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ABSTRACT
THE EFFECT OF MATERNAL ANTIBODIES ON ANTI-VIRAL IMMUNITY IN INFANT
MICE
Elinor Willis
Scott E. Hensley
Infants are particularly vulnerable to infection and severe disease, yet we lack effective
vaccines for this population. While maternal antibodies can provide protection, they also
inhibit the infant’s de novo antibody response. Furthermore, maternal antibodies can
exacerbate disease in some contexts. Thus we need better vaccination strategies to
protect infants. Here, we establish mouse models of influenza virus- and flavivirusspecific maternal antibody transfer. We show that influenza virus-specific maternal
antibodies protect infant mice from influenza disease and that Zika virus-specific
maternal antibodies protect infants from Zika virus-mediated disease. Dengue virusspecific maternal antibodies neither protect from nor exacerbate disease during Zika
virus infection of infant mice. We further demonstrate that influenza virus-specific
maternal antibodies inhibit infants’ responses to conventional influenza vaccines. To
solve this problem, we show that a novel vaccine, nucleoside-modified mRNA
encapsulated in lipid nanoparticles (mRNA-LNP) encoding influenza hemagglutinin,
overcomes maternal antibody inhibition by prolonged establishment of germinal centers.
mRNA-LNP vaccination offers a promising means of eliciting protective immune
responses in infants in the presence of maternal antibodies. These results have
important implications for the design of vaccines for use in mothers and infants.
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CHAPTER 1: INTRODUCTION
In a complex world of host-pathogen interactions, infection during infancy can
lead to severe outcomes. The World Health Organization estimated that 2.5 million
children under 5 years old died of infectious disease in 2015 (World Health Organization,
2016). These deaths account for over 40% of all deaths of children under 5 (UNICEF,
2018; World Health Organization, 2016). Infants are born with an immune system that is
both immature and adapted to the unique needs of an individual first encountering a
complex microbial environment (Restori et al., 2018). Furthermore, development of
many organ systems continues after birth, including the brain and lungs (Lewin and
Hurtt, 2017; Semple et al., 2013) and infections during infancy can have long-lasting
consequences (Restori et al., 2018). Special care must therefore be taken to protect
infants from infectious diseases.
Vaccination has successfully reduced the number of childhood deaths due to
infectious diseases, including measles, mumps, rubella, polio, and others (Roush and
Murphy, 2007), but many of these vaccines are not used in the youngest infants due to
efficacy and safety concerns (Sanchez-Schmitz and Levy, 2011; Wood and Siegrist,
2011). Additionally, as described in detail below, the infant immune system differs from
that of adults in several important aspects. Therefore, it is essential to improve our
understanding of infant immune responses to infection and vaccination.
Infant Immune System
Studies in both humans and mice have shown that infant antibody responses do
not fully match those of adults (reviewed in (Adkins et al., 2004; Hodgins and Shewen,
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2012; Restori et al., 2018; Siegrist and Aspinall, 2009)). Human neonates have a higher
proportion of naïve B cells than adults (Pettengill et al., 2016), and those naïve B cells
express fewer co-receptors required for activation (e.g. CD80 and CD86) (Kaur et al.,
2007; Pettengill et al., 2016). B cell follicles arise before birth but germinal centers (GCs)
begin to appear several weeks after birth (Asano et al., 1993; Kasajima-Akatsuka and
Maeda, 2006; Steiniger et al., 2007; Westerga and Timens, 1989). Infants up to 8
months old display less somatic hypermutation (Ridings et al., 1998) and a defect in
class switching (Pettengill et al., 2016), suggesting that GCs are not yet fully active.
However, human neonatal peripheral B cells respond similarly to adult peripheral B cells
to antigen receptor cross-linking and CpG oligodeoxynucleotide stimulation (Tasker and
Marshall-Clarke, 2003). In neonatal mice, organized B cell follicles and follicular dendritic
cells begin to appear 7-11 days postnatally (Cupedo et al., 2004; Hiramoto et al., 2005),
but reach similar number and size to adults at 3-4 weeks of age (Bajenoff and Germain,
2009; Munguia-Fuentes et al., 2017). GC responses to immunization are delayed and
reduced compared to adults (Munguia-Fuentes et al., 2017). Space in infant GCs and
bone marrow niches is limited, possibly leading to competition among B cells for
activation and survival signals (Siegrist and Aspinall, 2009). Limited GC responses lead
to reduced affinity maturation and delayed class switching and may predispose infant B
cells to memory rather than plasma cell fate (Siegrist and Aspinall, 2009).
Neonatal T cells differ from adult T cells as well. Neonatal CD4+ T cells are
biased toward Th2 responses (Faucette et al., 2015; Forsthuber et al., 1996; Palmeira et
al., 2012; Ridge et al., 1996). In particular, neonatal mice infected with influenza virus
generate a Th2 cytokine response in the lung (Lines et al., 2010). Th2 responses can
contribute to both protection and pathology during influenza virus infections. Th2
2

polarization supports antibody production, which can provide sterilizing immunity against
influenza virus infection. Conversely, Th2 responses can lead to pulmonary
immunopathology (Graham et al., 1994). Finally, many studies have shown that certain
adjuvants or delivery methods can elicit a Th1 response in infants (Brazolot Millan et al.,
1998; Forsthuber et al., 1996; Marchant et al., 1999; Martinez et al., 1997; Sarzotti et al.,
1996; Siegrist et al., 1999).
Neonatal CD8+ T cells seem to be less functional than adult CD8+ T cells.
Neonatal murine CD8+ T cells produce less IFNγ than adult CD8+ T cells during
influenza virus infection; furthermore, neonatal mice with adoptively transferred adult
CD8+ T cells have less virus in the lungs, and this effect is dependent on IFNγ (You et
al., 2008). Another study showed a defect in neonatal CD8+ T cell migration to the lung
during influenza virus infection in mice (Lines et al., 2010). However, infant T cells may
fulfill protective roles by other means, as γδ T cells were shown to contribute to
protection during neonatal influenza virus infection in mice (Guo et al., 2018).
Vaccination of Infants: Current Status
Although childhood vaccination has saved many lives, there are still gaps in our
ability to vaccinate. Vaccine strategies must overcome the obstacles described in the
previous section to generate long-lasting, protective immune responses in infants. Most
childhood vaccines are not licensed for the youngest infants, who are often the most
vulnerable to infection or severe disease. Only the hepatitis B, oral polio, and BCG
vaccines are used in neonates (World Health Organization, 2018b). Several other
vaccines are first administered at 6 weeks (e.g. DTaP, Haemophilus influenzae type b,
pneumococcal conjugate, and rotavirus), and many are not recommended until 6-18
3

months of age (e.g. measles, mumps, rubella, Japanese encephalitis, yellow fever,
typhoid, cholera, hepatitis A, varicella, and influenza) (World Health Organization,
2018b). Many of these vaccines require multiple doses over several months to achieve
full protection (World Health Organization, 2018b), and thus the child may remain
vulnerable even after receiving 1-2 doses of the vaccine. Other vaccines are not
administered to young children due to adverse events. The live attenuated influenza
vaccine was associated with increased episodes of wheezing in children under 2 years
of age and thus is not recommended for that age group (Beeler and Eichelberger, 2013;
Bonati and Clavenna, 2012). The dengue virus vaccine CYD-TDV is currently only
recommended in children over 9 years of age who are already seropositive (World
Health Organization, 2018a). Even more concerning, we lack vaccines altogether for
some diseases that cause significant morbidity and mortality in infants, including group B
streptococcus and respiratory syncytial virus. Due to a combination of lack of efficacy
and unacceptable safety profiles, there remains an unmet need for vaccination
strategies to protect infants.
Maternal Vaccination
One solution to the problem of protecting infants from infectious diseases in the
face of inadequate infant vaccines is through maternally derived immunity. Vertebrate
mothers transfer various immune components to their offspring, most notably antibodies
(Faucette et al., 2015; Grindstaff et al., 2003; Hodgins and Shewen, 2012; Jennewein et
al., 2017; Siegrist, 2003). In mammals, maternal antibodies (matAbs) are transferred in
utero or through colostrum or milk; they then enter systemic circulation of the fetus or
neonate and provide protection from infections (Jennewein et al., 2017).
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Vaccination with Tdap and inactivated influenza vaccines is routinely
recommended during pregnancy, and other vaccines (meningococcal polysaccharide,
hepatitis A and B, inactivated poliovirus, rabies, and yellow fever) are used in certain
circumstances (Centers for Disease Control and Prevention, 2016). Historically,
vaccination during pregnancy has been intended to protect the pregnant woman from
infectious diseases that are especially severe during pregnancy (e.g. influenza).
However, the use of maternal vaccination to protect the infant as well has recently
gained support.
The immune system undergoes complex changes during pregnancy (Mor and
Cardenas, 2010). Therefore, vaccines must be tested in pregnant women to ensure that
they are both safe and immunogenic. Inactivated vaccines as well as some live vaccines
have been used safely in pregnant women (Keller-Stanislawski et al., 2014). Many
studies have examined antibody responses to vaccines in pregnant women, in particular
inactivated influenza and Tdap vaccines. These vaccines are generally able to elicit
antibody responses in pregnant women, although whether these responses are similar
to those of non-pregnant women in magnitude and quality is unclear (Marchant et al.,
2017; Munoz et al., 2018).
Protection of infants by maternal antibodies has been demonstrated in many
studies. Studies in humans have focused on pertussis and influenza. Maternal Tdap
vaccination was 90-91% effective in preventing pertussis during the first two months of
life in two retrospective studies (Amirthalingam et al., 2014; Baxter et al., 2017), and
similar findings were reported in a case control study (Campbell et al., 2018; Dabrera et
al., 2015). Higher titers of anti-influenza virus antibody measured in cord blood led to
later age at infection, suggesting that matAbs can protect infants (Puck et al., 1980), and
5

a large randomized double-blind placebo-controlled trial demonstrated a maternal
inactivated influenza vaccine efficacy of 50% in infants up to 6 months old (Madhi et al.,
2014). A recent meta-analysis concluded that maternal vaccination is effective in
protecting infants from influenza disease (Nunes and Madhi, 2018). Protection of infants
from influenza has been recapitulated in mouse (Hwang et al., 2010; Mbawuike et al.,
1990; Radu et al., 2001; van der Lubbe et al., 2017) and ferret models (Husseini et al.,
1984; Sweet et al., 1987). MatAb-mediated protection from dengue has not been studied
in as much detail. Two studies found a positive correlation between matAb titer and age
at infection (Kliks et al., 1988; Libraty et al., 2009). A third study did not find a correlation
between matAb titer and age at infection but did find that most infected infants had a low
matAb titer against the infecting serotype (Simmons et al., 2007).
Transfer of Maternal Antibodies
Maternal IgG is transferred to the offspring by the neonatal Fc receptor (FcRn)
(Palmeira et al., 2012; Roopenian and Akilesh, 2007). FcRn has high affinity for IgG at
acidic pH and low affinity at physiological neutral pH (Rodewald, 1976; Vaughn and
Bjorkman, 1998). IgG is taken up into the cell by fluid-phase endocytosis and then binds
to FcRn in the acidic endosome (Rodewald and Kraehenbuhl, 1984). IgG is then
released at the basolateral surface into the fetal/infant tissues. In humans, FcRn is
expressed on syncytiotrophoblasts in the placenta, leading to IgG transfer from maternal
to fetal blood during pregnancy (Kristoffersen and Matre, 1996; Leach et al., 1996;
Simister et al., 1996). In rodents, some transfer occurs across the yolk sac (Brambell
and Halliday, 1956), but the majority of IgG transfer occurs via absorption from milk, as
neonatal rodents express FcRn in the small intestine for ~2 weeks post birth (Hemmings
and Morris, 1959; Lee et al., 2016; Simister and Rees, 1985). In other species such as
6

ungulates, IgG is transferred only in colostrum (first milk) (Hurley and Theil, 2011).
Human infants do not absorb IgG from colostrum or milk (Brandtzaeg, 2003; Hurley and
Theil, 2011).
FcRn does not bind to IgM, IgA, IgD, or IgE (Kohler and Farr, 1966; Roopenian
and Akilesh, 2007). There is some evidence for IgE transfer as a passenger in immune
complexes with IgG (Bundhoo et al., 2015). In humans and rodents, IgM and IgA are not
transferred in utero, and IgM is not absorbed systemically from milk (Kohler and Farr,
1966; Malanchere et al., 1997). While IgA is the major immunoglobulin in milk, it likely
plays a very minor role, if any, in systemic protection of the neonate because it does not
bind to FcRn. IgA is not absorbed systemically in neonatal mice (Malanchere et al.,
1997). There is conflicting evidence for and against systemic absorption of IgA from milk
in humans (Brandtzaeg, 2003; Ogra et al., 1977; Vukavic, 1983), but the receptor that
could mediate this absorption is not identified and maternal IgA has not been shown to
play a protective role against infections outside of the gastrointestinal tract.
The ratio of IgG in the cord blood of the infant compared to the mother’s blood is
~1:1, and can be higher (Palmeira et al., 2012). There is some evidence that transfer of
antibodies depends on the antigenic specificity (de Moraes-Pinto et al., 1996;
Dechavanne et al., 2015; Silveira Lessa et al., 2011; van den Berg et al., 2010),
although the mechanism by which this would occur is unknown since the FcRn binds the
Fc region of IgG. It is possible that this may be due to different IgG subclass composition
of the antibody response to different types of pathogens, e.g. polysaccharide-specific
antibodies tend to be of the IgG2 subclass, which is transported across the placenta less
efficiently than other subclasses (Barrett and Ayoub, 1986; Malek et al., 1994).
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FcRn has high affinity for monomeric IgG and low affinity for IgG complexes
(Dashivets et al., 2015); however, two studies of placental explants reported antigen or
virion transfer in the presence of matAbs (Maidji et al., 2006; May et al., 2009). Whether
this occurs in vivo is unknown. FcRn also plays an important role in maintaining IgG
levels in the serum (Ghetie et al., 1996; Junghans and Anderson, 1996; Roopenian et
al., 2003).
Maternal antibodies wane over time in the infant. IgG has a half-life of ~7 days in
adult mice (Vieira and Rajewsky, 1986, 1988). The half-life of maternal IgG in infant mice
is similar or somewhat longer, with different studies reporting 7-16 days (Lee et al.,
2016; Malanchere et al., 1997; Zhang et al., 2013a). In adult humans, IgG1, IgG2, and
IgG4 have a half-life of ~21 days (Morell et al., 1970), while that of IgG3 is ~7 days due
to decreased binding to FcRn (Stapleton et al., 2011). The half-life of matAbs in human
infants has been estimated by many groups and ranges from 23-150 days although most
studies report 30-50 days (Andiman et al., 1990; Brinkhof et al., 2013; Chau et al., 2009;
Chu et al., 2014; Lee et al., 2001; Lennon and Black, 1986; Libraty et al., 2009; Nunes et
al., 2015; Nyiro et al., 2015; Palasanthiran et al., 1994; Parekh et al., 1993; Sarvas et al.,
1993; Shahid et al., 1995; Simmons et al., 2007; Thompson et al., 2016; van Der Zwet et
al., 2002; van Maanen et al., 1992; Van Oirschot et al., 1991; van Panhuis et al., 2011;
Watanaveeradej et al., 2003; Williams et al., 1995; Wilson et al., 2001; Zuccotti et al.,
2010). Some studies report a biphasic decay pattern (van Panhuis et al., 2011; Williams
et al., 1995). It is unclear why the half-life of maternal IgG in infants is longer than that of
IgG measured in adults. Overexpression of FcRn increased the half-life of IgG in mice
(Cervenak et al., 2011), but it is unknown whether FcRn expression is increased in the
endothelium of human infants. Alternatively, modifications of IgG that occur during
8

pregnancy such as differential glycosylation could affect binding to FcRn, but this is
controversial (Bondt et al., 2014; Jennewein et al., 2017).
Interestingly, the half-life of matAbs varies between antigens, although this may
be due to differing methods of antibody quantification and limited availability of
longitudinal serum samples from infants. For influenza virus-specific matAbs, the
estimates in human infants range from 42 days (Nunes et al., 2015) to 83 days (Zuccotti
et al., 2010). For dengue virus-specific matAbs, most estimates range from 36 to 42
days (Chau et al., 2009; Libraty et al., 2009; Simmons et al., 2007; Watanaveeradej et
al., 2003), but one study (van Panhuis et al., 2011) found a biphasic decay with the halflife of the first phase at 24-29 days and the second phase 44-150 days. De novo
infection during the second phase could not be ruled out in that study.
The duration of protection from matAbs is generally considered to be several
months (Brandtzaeg, 2003), although this depends on the accepted protective titer for
each pathogen and sensitivity of antibody measurement methods. For influenza, most
infants have a hemagglutination inhibition (HAI) titer of 1:40 until approximately 2 months
of age (Nunes et al., 2015; Zuccotti et al., 2010). An HAI titer of 1:40 is generally
accepted to provide protection in 50% of adults (Hobson et al., 1972); however, one
study estimated that infants require an HAI titer of 1:110 for 50% protection and 1:629
for 90% protection (Black et al., 2011). Because no influenza vaccine is approved for
use in infants younger than 6 months of age, this leaves a gap in which the infants are
vulnerable.
The seroprotective level of dengue virus-specific matAbs is unclear and is
complicated by the phenomenon of antibody-dependent enhancement discussed in the
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next section. However, several studies have estimated the duration of protection
provided by dengue virus-specific matAbs using reasonable titer cutoffs. One study
found that a neutralizing matAb titer of 1:50-1:100 against DENV3 was likely to confer at
least partial clinical protection to children (Libraty et al., 2009), and a median neutralizing
matAb titer of 1:50 was found to persist until 2.4 to 6 months of age, depending on the
dengue virus serotype, in another study (van Panhuis et al., 2011). A third study found
that neutralizing matAbs fell below 1:50 for all serotypes by 3-6 months of age (Pengsaa
et al., 2006). Thus matAb-mediated protection from dengue is likely to last for only a few
months, yet the available vaccine is not licensed children under 9 years of age or for
dengue-naïve children.
Detrimental Effects of MatAbs
While matAbs are clearly able to protect infants from many diseases, they can
have detrimental effects on the infant as well. The phenomenon of matAb inhibition of
infant immune responses has been widely observed for many antigens and will be
discussed in the next section. Another serious effect of matAbs on the infant occurs
during flavivirus infections. Flaviviruses are a genus of viruses that includes the
important human pathogens dengue virus, yellow fever virus, West Nile virus, St. Louis
encephalitis virus, and Zika virus, as well as many other lesser-known species (Kuno et
al., 1998). In particular, the four serotypes of dengue virus (DENV) circulate widely in
tropical regions of the world (Guzman and Harris, 2015). Most DENV infections result in
relatively mild illness, but some patients suffer from a more severe form, called dengue
hemorrhagic fever or dengue shock syndrome (Ranjit and Kissoon, 2011). The main
hypothesis for the development of severe disease is antibody-dependent enhancement
(ADE), the mechanism of which is not entirely clear. The original model proposed an
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enhancement of infection, in which pre-existing non-neutralizing antibodies facilitate viral
infection of Fc receptor-bearing cells and increased viral load (Halstead, 2003).
Increased viral load may lead to pathologic cytokine production and vascular leakage
(Guzman and Harris, 2015). A striking variation on this model was recently proposed, in
which DENV infection leads to production of antibodies with high affinity for the
activating FcγRIIIA, resulting in thrombocytopenia and severe disease (Wang et al.,
2017).
Because antibodies specific for certain conserved epitopes of the flavivirus E
protein are cross-reactive but not neutralizing, ADE is hypothesized to occur during a
heterologous secondary dengue virus infection (e.g. infection with DENV-2 in an
individual previously exposed to DENV-1). Epidemiological investigations showed that
there are two peaks of infection in children, in infants less than 1 year old and in children
4-8 years old (Halstead et al., 2002). While the peak in older children was shown to be
due to secondary infections, the infants had primary DENV infections (Halstead et al.,
1970). This pattern, combined with the observation that maternal and infant plasma
could enhance in vitro infection, resulted in the hypothesis that DENV infection in an
infant may result in ADE and severe disease if the infant has received matAbs that bind
but do not neutralize the infecting virus (Chau et al., 2008; Halstead, 1970; Halstead et
al., 2002; Kliks et al., 1988). While this hypothesis is challenging to directly test in
humans, ADE due to maternal antibodies has been demonstrated in mouse models of
DENV infection (Lee et al., 2016; Martinez Gomez et al., 2016; Ng et al., 2014).
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Inhibition of de Novo Antibody Responses by MatAbs
As discussed in the previous section, matAbs can have detrimental as well as
beneficial effects on the infant’s immune system and disease severity. While
enhancement of infant disease due to non-neutralizing matAbs is specific to certain
groups of viruses, the phenomenon of matAb inhibition of infant antibody responses
occurs more generally. Inhibition of infant de novo antibody responses has been
observed after administration of various types of vaccines, including live attenuated
viruses, inactivated viruses, toxoids, DNA vaccines, vectored vaccines, protein subunits,
and virus-like particles, as well as in at least 11 species including humans, macaques,
and rodents (Abdelwhab et al., 2012; Albrecht et al., 1977; Appaiahgari et al., 2014;
Bandrick et al., 2014; Buonavoglia et al., 1994; Chen et al., 2007; Dagan et al., 2000;
Ellis et al., 2014; Hardy-Fairbanks et al., 2013; Jensen et al., 2015; Johansson et al.,
2008; Kitikoon et al., 2006; Lardinois et al., 2016; Maertens et al., 2016; Martella et al.,
2005; Nohynek et al., 1999; Pertmer et al., 2000; Premenko-Lanier et al., 2006; Prince et
al., 1979; Sandbulte et al., 2014; Suguitan et al., 2014; van Maanen et al., 1992; Van
Oirschot et al., 1991; Welter et al., 2000; Wilson et al., 2001; Xiang and Ertl, 1992).
Inhibition has been demonstrated for both human and veterinary pathogens. A recent
meta-analysis of serological data from randomized clinical trials concluded that preexisting antibody inhibited infants’ vaccine responses for 20 of the 21 antigens from
studied (Voysey et al., 2017).
MatAb-mediated inhibition of antibody responses to influenza vaccines has been
demonstrated in multiple animal species, both as models for human disease and as
species clinically affected by influenza: mice (Chen et al., 2007; Pertmer et al., 2000;
Reuman et al., 1983), ferrets (Suguitan et al., 2014), chickens (Abdelwhab et al., 2012;
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Lardinois et al., 2016; Maas et al., 2011; Richard-Mazet et al., 2014), horses (Cullinane
et al., 2001; van Maanen et al., 1992; Van Oirschot et al., 1991; Wilson et al., 2001), and
pigs (Kitikoon et al., 2006; Sandbulte et al., 2014). One small study conducted in human
infants (Halasa et al., 2008) also demonstrated a lower seroconversion rate and lower
post-vaccination titer in infants that had higher pre-vaccination titers. As maternal
vaccination during pregnancy has become more common, the potential effects on
subsequent vaccination of infants will become more prominent.
The mechanism(s) by which matAbs inhibit de novo antibody responses are
unclear. The leading hypotheses include (1) neutralization of live virus by matAbs,
limiting infection and thus antigen load; (2) epitope masking, in which matAbs bind
certain epitopes on the vaccine antigen and prevent B cell receptor binding and B cell
activation; (3) clearance of antigen through Fc-mediated uptake of immune complexes
by phagocytic cells; and (4) engagement of the inhibitory FcγRIIB receptor on B cells by
matAb-vaccine antigen immune complexes, preventing B cell activation (reviewed in
(Siegrist, 2003)). Neutralization of live virus by matAbs (Albrecht et al., 1977;
Appaiahgari et al., 2014; Buonavoglia et al., 1994; Ellis et al., 2014; Jensen et al., 2015;
Martella et al., 2005; Premenko-Lanier et al., 2006; Prince et al., 1979; Sandbulte et al.,
2014) likely explains the inhibition of antibody responses to live virus vaccines, but
cannot account for inhibition of non-replicating antigens (Abdelwhab et al., 2012;
Bandrick et al., 2014; Dagan et al., 2000; Hardy-Fairbanks et al., 2013; Johansson et al.,
2008; Kitikoon et al., 2006; Maertens et al., 2016; Xiang and Ertl, 1992). Epitope
masking is an attractive hypothesis but difficult to demonstrate in vivo, in part due to
polyclonality of matAbs, and difficult to disentangle from the effects of Fc-mediated
clearance of vaccine antigen. Epitope masking leading to a shift in antibody repertoire
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has been shown in a mouse model of influenza infection and vaccination using
monoclonal antibody and recombinant virus (Angeletti et al., 2017), but there is no
conclusive evidence that this occurs in the presence of matAbs. Immune complexes
(ICs) are likely taken up efficiently by phagocytic cells (Manca et al., 1991; Regnault et
al., 1999), but it is unlikely that this potential mechanism could account for the degree of
inhibition (including complete inhibition in some systems) seen in the presence of
matAbs. The lack of inhibition of T cell responses in some studies (Bandrick et al., 2014;
Capozzo et al., 2004; Hassett et al., 1997; Pomorska-Mol et al., 2010; Rigato et al.,
2012; Sandbulte et al., 2014; Sedegah et al., 2003; Van Loock et al., 2004; Weeratna et
al., 2001) suggests that vaccine antigen, possibly in the form of ICs, is phagocytosed
and presented by antigen presenting cells, but this remains uncertain as other studies
have not found intact T cell responses in the presence of matAbs (Premenko-Lanier et
al., 2006; van Rooij et al., 2006; Xiang and Ertl, 1992). One study reported matAb
inhibition of de novo responses through engagement of FcγRIIB (Kim et al., 2011), but
did not actually examine the role of FcγRIIB and did not utilize matAbs. Increasing
antigen dose decreases the effect of matAb inhibition (Bailey et al., 1998; Burtonboy et
al., 1991; Coyne, 2000; Elazab et al., 2010; Hsieh et al., 2010), but increased amounts
of antigen would facilitate increased binding to FcγRIIB as well as BCRs (Siegrist, 2003).
MatAbs likely inhibit de novo antibody responses through a combination of mechanisms
in which the ratio of antigen to antibody is important, although it remains unclear how
these factors interact.
Vaccination Strategies to Overcome MatAb Inhibition
Inhibition of de novo infant antibody responses to vaccination, combined with
waning matAb titers, results in a window of vulnerability during which the infant has not
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yet generated active immunity but also lacks passive immunity and therefore is
vulnerable to infection and/or severe disease (Figure 1.1A,B). An ideal vaccination
strategy would elicit protective de novo immune responses in the infant in the presence
of high matAb titers (Figure 1.1C), but such a strategy has proved elusive despite many
attempts.
Many vaccination strategies rely on delayed vaccination or multiple booster
doses to achieve antibody responses and/or protection in vaccinees. In fact, measles
vaccine is administered at 9-12 months of age in part due to interference by matAbs
(Edwards, 2015). However, this strategy does not solve the window of vulnerability
problem since it depends on matAbs waning to low, non-protective levels (Figure 1.1B).
A promising strategy to circumvent matAb inhibition is to use vectored or
plasmid-based vaccines. These vaccines do not contain antigens to which matAbs can
bind and therefore may avoid some of the inhibition mechanisms discussed above. Viral
vectored vaccines have successfully elicited de novo antibody responses in poultry
(Bertran et al., 2018; Bublot et al., 2007; Kilany et al., 2015; Sonoda et al., 2000),
although not all vaccines elicit full protection from challenge. However, vectored
vaccines have been less successful in mammals (Capozzo et al., 2004; Ramirez et al.,
2010; Welter et al., 2000). One study found that an adenovirus-vectored vaccine
expressing two influenza virus proteins (HA and NP) elicited an antibody response in
pigs in the presence of matAbs, but this response was delayed and the authors did not
control for the effect of matAb in the absence of vaccination (Wesley and Lager, 2006).
Another study found that an alphavirus-vectored DENV prM-E vaccine elicited an
antibody response in mice in the presence of matAbs, but the animals were not
challenged, raising the question of whether the antibodies elicited would protect from or
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enhance disease during heterologous challenge (White et al., 2007). DNA vaccines have
also shown varying degrees of success in some studies (Capozzo et al., 2004; Hassett
et al., 1997; Hsieh et al., 2010; Manickan et al., 1997; van Drunen Littel-van den Hurk et
al., 2010; van Rooij et al., 2006), but were unsuccessful in others (Bot and Bona, 2002;
Chen et al., 2007; Monteil et al., 1997; Pertmer et al., 2000; Radu et al., 2001; Siegrist et
al., 1998). Thus, eliciting protective antibody responses in the presence of matAbs
remains a challenge.
mRNA vaccines
mRNA vaccines can be divided into two broad categories: self-amplifying and
non-amplifying mRNA. Self-amplifying mRNA (SAM) is derived from a viral vector and
consists of mRNA encoding the antigen of interest and viral vector RNA replication
machinery that amplifies the mRNA within the target cell (Geall et al., 2012). Nonreplicating mRNA encodes only the antigen of interest. In both cases, the mRNA is
encoded by a DNA template, which is transcribed in vitro. The resulting mRNA molecule
is typically complexed with carrier molecule(s) that protect the mRNA from extracellular
degradation and facilitate entry into cells. Several types of carriers have been used,
including protamine, dendrimers, and cationic lipids, and these molecules are most often
formulated into liposomes or nanoparticles (Pardi et al., 2018b). Inside the cell, the
mRNA is translated and the protein antigen is produced in vivo. Intravital imaging of
Luciferase encoded by mRNA delivered in lipid nanoparticles has demonstrated that
mRNA is translated for at least 10-14 days post injection (Pardi et al., 2018a; Pardi et al.,
2015).
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mRNA-based vaccination offers several advantages over other vaccine platforms
(reviewed in (Pardi et al., 2018b)). Nucleic acid production and vaccine formulation are
independent of the target, so it is easily adapted to emerging pathogens such as
pandemic influenza and Zika virus (Hekele et al., 2013; Pardi et al., 2017; Richner et al.,
2017a). Additionally, cell culture- and egg-free vaccine production facilitates scalability.
There are no concerns about the production of live pathogens or ensuring inactivation.
Insertional mutagenesis is not possible because mRNA cannot integrate into host.
Finally, because antigen is produced in vivo, it acquires the appropriate posttranslational modifications such as glycosylation.
Although concerns over stability, innate immunogenicity, and the lack of
appropriate delivery systems initially delayed development, mRNA-based vaccines have
recently emerged as a promising platform (Pardi et al., 2018b). Several technological
advances made this possible. Modifications that increase the resemblance of vaccine
mRNA to naturally occurring cellular mRNAs, such as addition of a 3’ polyA tail and 5’
capping, increase stability and translatability (Holtkamp et al., 2006; Kuhn et al., 2010).
Optimization of the 5’ and 3’ untranslated regions (UTRs) further increases translation
efficiency (Holtkamp et al., 2006; Ross and Sullivan, 1985), as does the use of modified
nucleosides such as replacement of uridine with pseudouridine (Kariko et al., 2008). The
use of modified nucleosides provides the additional benefit of reducing activation of
innate immune sensors that would otherwise lead to damaging proinflammatory cytokine
release (Kariko et al., 2008). High performance liquid chromatography (HPLC)
purification eliminates double stranded DNA contaminants and further decreases innate
immune activation (Kariko et al., 2011).
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Together, these improvements have enabled mRNA vaccines to demonstrate
immunogenicity and protection in animal models and enter human trials (Bahl et al.,
2017; Brazzoli et al., 2016; Chahal et al., 2016; Hekele et al., 2013; Liang et al., 2017;
Lindgren et al., 2017; Lutz et al., 2017; Magini et al., 2016; Pardi et al., 2018a; Pardi et
al., 2017; Pardi et al., 2018c; Petsch et al., 2012; Richner et al., 2017a; Richner et al.,
2017b; Schnee et al., 2016). Several reports showed that prime-boost regimens of SAM
or unmodified, unpurified, protamine-complexed mRNA encoding influenza
hemagglutinin were immunogenic and protective in mice, although the results were less
encouraging in ferrets and pigs (Brazzoli et al., 2016; Hekele et al., 2013; Petsch et al.,
2012). Another study showed that nucleoside-modified lipid nanoparticle-complexed
mRNA vaccine (mRNA-LNP) encoding an H1 hemagglutinin protected mice against both
homologous (H1) and heterologous (H5) challenges (Pardi et al., 2018c), suggesting
that this vaccine platform might be able to provide broad protection from emerging
influenza strains. Multiple studies have demonstrated immunogenicity of various types of
hemagglutinin-encoding mRNA vaccines in non-human primates (Bahl et al., 2017;
Liang et al., 2017; Lindgren et al., 2017; Lutz et al., 2017). The emergence of Zika virus
prompted the rapid development of mRNA vaccines, providing an illustration of the
adaptability of this platform. One study demonstrated that a nucleoside-modified mRNALNP vaccine encoding the prM and E proteins of Zika virus was immunogenic and
protective in mice and nonhuman primates (Pardi et al., 2017). Another group showed
that a similar vaccine protected adult mice and prevented congenital Zika infection in
fetal mice (Richner et al., 2017a; Richner et al., 2017b).
Human clinical trials are underway testing both prophylactic infectious disease
and therapeutic cancer mRNA vaccines (Grunwitz and Kranz, 2017; Pardi et al., 2018b).
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Two phase I clinical trials of prophylactic infectious disease mRNA vaccines have been
conducted, and the vaccines appeared to be safe and have reasonable immunogenicity
profiles, although there is room for improvement (Alberer et al., 2017; Bahl et al., 2017).
Other clinical trials for preventative infectious disease vaccines are ongoing (Pardi et al.,
2018b). The use of mRNA vaccines as a therapeutic option for cancer is also a
burgeoning field (reviewed in (Grunwitz and Kranz, 2017)). Multiple phase I and II clinical
trials have been conducted or are in progress (Grunwitz and Kranz, 2017). While these
vaccines represent great variety in delivery mechanisms and targets due to the unique
challenges of generating anti-tumor responses, they seem to be well-tolerated and show
some promise with regards to immunogenicity (Kranz et al., 2016; Kubler et al., 2015;
Rittig et al., 2011, 2016; Sebastian et al., 2011; Weide et al., 2008; Weide et al., 2009).
However, the studies described above were conducted in adults. Very few have
investigated the use of mRNA vaccines in neonates. One study showed that a rabies
virus glycoprotein-encoding mRNA vaccine complexed with protamine in the RNActive
formulation elicited virus neutralizing titers in neonatal pigs (Schnee et al., 2016). In
another study, a vaccine using the same platform was able to protect neonatal mice from
influenza challenge (Petsch et al., 2012). However, other types of mRNA vaccines have
not been tested in neonates, and no mRNA vaccines have been assessed in the
presence of matAbs.
Experimental Questions
Infants must adjust to a complex environment and negotiate host-pathogen
relationships while building an immune repertoire that will protect them from subsequent
challenges. Yet we do not sufficiently understand how the infant immune system
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interacts with extrinsic factors such as maternally derived antibodies and vaccines.
Furthermore, current vaccine options for infants are inadequate. In chapter two, we
establish a mouse model of influenza virus-specific matAbs and employ our model to
examine mechanisms of matAb inhibition and to investigate better vaccine strategies.
We find that matAbs protect neonatal mice from influenza disease and prevent viral
replication in the lungs. Moreover, influenza virus-specific matAbs inhibit de novo
antibody responses to conventional live and inactivated influenza vaccines in infant
mice. However, we overcome this inhibition using a nucleoside-modified mRNA-LNP
vaccine encoding the influenza virus glycoprotein hemagglutinin (Pardi et al., 2018a;
Pardi et al., 2018c). The HA mRNA-LNP vaccine elicits robust serum antibody titers and
sustained germinal center responses leading to protection of infant mice vaccinated in
the presence of influenza virus-specific matAbs. Because the mRNA-LNP platform is
easily adaptable to different pathogens, mRNA-LNP vaccination offers a promising
strategy for protection of infants in the presence of matAbs.
In chapter three, we apply our murine maternal antibody model to an emerging
pathogen. Zika virus emerged as a public health concern in 2015 due to an alarming
association with neurological disease in Brazil that had not been apparent in previous
ZIKV outbreaks. One possible explanation for this more severe disease is that flavivirusspecific matAbs could enhance ZIKV disease. ZIKV and DENV are closely related
flaviviruses and share cross-reactive epitopes on the E protein (Barba-Spaeth et al.,
2016), and DENV is endemic in Brazil (Messina et al., 2014). In this chapter, we
determine whether monoclonal antibodies elicited by other flaviviruses can enhance
ZIKV infection in vitro. Using a panel of mAbs, we find that 3 of 54 mAbs can enhance
ZIKV infection in an Fc receptor-bearing monocytic cell line. We then turn to the question
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of whether flavivirus-specific matAbs enhance ZIKV disease in vivo. MatAbs are an
excellent system to test the effect of pre-existing antibodies in the absence of memory B
cells. Furthermore, ZIKV infection of infants may have long-lasting consequences since
the nervous system continues to develop during infancy (Semple et al., 2013), yet ZIKV
infection during infancy has not received enough attention (Lebov et al., 2018). We
adapt our mouse model from chapter two to examine the effect of DENV- and ZIKVspecific matAbs on ZIKV infection and disease outcomes of infant mice. We find that
ZIKV-specific matAbs protect mice from ZIKV challenge, but DENV-specific matAbs
neither enhance nor protect from ZIKV disease. These results have implications for
flavivirus vaccine development and use in pregnant women and infants.
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Figure 1.1

Figure 1.1. Infant vaccination strategies in the presence of matAbs.
MatAb levels (black line) are initially above the protective threshold, but wane over time
post birth. A, Vaccination in the presence of high levels of matAbs results in inhibition of
the infant’s de novo antibody response and the infant remains vulnerable to infection. B,
A common workaround for the problem of matAb inhibition of vaccine responses is to
delay vaccination until matAb levels have fallen to a low, non-inhibitory level. However,
this leaves a window of vulnerability during which the infant is not protected. C, The ideal
vaccination strategy would elicit de novo antibody responses in the presence of high
levels of matAbs.
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CHAPTER 2: NUCLEOSIDE-MODIFIED mRNA VACCINATION OVERCOMES
MATERNAL ANTIBODY INHIBITION OF DE NOVO IMMUNE RESPONSES
Parts of this chapter have been submitted for publication as:
Willis, E., Pardi, N., Parkhouse, K., Mui, B. L., Tam, Y. K., Weissman, D., and Hensley,
S. E. Nucleoside-modified mRNA vaccination overcomes maternal antibody inhibition of
de novo immune responses.

Summary
In a complex world of host-microbial interactions, infants are especially
vulnerable. While maternal antibodies provide protection, they can inhibit de novo
antibody responses elicited by infections and vaccinations in infants. Thus, there is a
need to develop new vaccines that elicit protective immune responses in the presence of
antigen-specific maternal antibodies. Here, we use a mouse model to demonstrate that
influenza virus-specific maternal antibodies inhibit de novo antibody responses elicited
by influenza virus infection and conventional influenza vaccines. Importantly, we find that
a novel vaccine, nucleoside-modified mRNA encapsulated in lipid nanoparticles (mRNALNP) encoding influenza virus hemagglutinin, overcomes this inhibition by establishing
prolonged germinal center reactions. mRNA-LNP vaccination therefore offers a
promising strategy for generating robust immune responses in the presence of maternal
antibodies in young infants.
Introduction
Infectious diseases cause considerable morbidity and mortality in infants. While
childhood vaccination has saved countless lives, we still lack many vaccines for the
youngest and most vulnerable infants. In particular, infants have the highest rate of
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hospitalization for severe lower respiratory tract infections (Greenbaum et al., 2014), yet
there are no licensed influenza vaccines for children under 6 months old. An alternative
strategy to protect young infants is through maternal vaccination, so that the mother
passes her antibodies to her infant. Maternal vaccination with inactivated influenza virus
during pregnancy was shown to confer 50% reduction in laboratory confirmed influenza
virus infections in a large randomized controlled trial (Madhi et al., 2014). However,
maternal antibodies wane over time, so active immunity must still be elicited in infants.
This leads to a new problem: maternal antibodies (matAbs) can inhibit de novo antibody
responses, leaving the child unprotected. Therefore, the true solution to the problem of
protecting infants must lie in better vaccine strategies.
Genetic vaccines offer a promising alternative to conventional vaccine strategies
because they are formulated with nucleic acid and carrier molecule(s), rather than
antigen to which matAbs will bind. DNA vaccines have shown success in some animal
models but not others in the presence of matAbs (Chen et al., 2007; Manickan et al.,
1997; Pertmer et al., 2000; Radu et al., 2001) and have not progressed to clinical use in
humans. Although mRNA vaccines lagged in development due to concerns over
instability, innate immunogenicity, and the lack of an efficient delivery system, recent
technological advances have brought mRNA vaccine platforms to the forefront of
vaccine development (Pardi et al., 2018b). Optimization of 5’ and 3’UTRs,
polyadenylation, and capping have led to increased stability and translation efficiency.
Use of chemically modified nucleosides and purification of full-length mRNA limit the
activation of innate immune sensors and further increase translation. New carrier
systems such as lipid nanoparticles allow efficient delivery in vivo (Pardi et al., 2018b).
Recently, several studies have demonstrated robust antibody responses elicited by
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mRNA vaccines in animals and humans, and protective efficacy in animal models (Bahl
et al., 2017; Brazzoli et al., 2016; Chahal et al., 2016; Hekele et al., 2013; Liang et al.,
2017; Lindgren et al., 2017; Lutz et al., 2017; Magini et al., 2016; Pardi et al., 2018a;
Pardi et al., 2017; Pardi et al., 2018c; Petsch et al., 2012; Richner et al., 2017a; Richner
et al., 2017b; Schnee et al., 2016). Encouragingly, one study showed that a protaminecomplexed mRNA vaccine could protect neonatal mice from influenza challenge (Petsch
et al., 2012). However, mRNA vaccines have not yet been tested in the context of
maternal antibodies. In this chapter, we establish a mouse model of influenza virusspecific matAbs and use it to determine the effects of matAbs on infant antibody
responses to infection and vaccination. We find that influenza virus-specific matAbs
inhibit infant antibody responses to conventional vaccines but a nucleoside-modified
mRNA-LNP vaccine expressing influenza hemagglutinin overcomes this inhibition.
Results
Maternal antibodies are efficiently transferred to infant mice
To examine the effect of matAbs on infant responses to influenza virus infection,
we established a mouse model in which we first intranasally infected adult female
BALB/c mice with a subclinical dose of the A/Puerto Rico/8/1934 (PR8) H1N1 influenza
virus strain. After these mice cleared the infection and mounted an antibody response
(confirmed by hemagglutination inhibition assays, HAIs), we mated them along with
unexposed control female mice to males and let them deliver pups (Fig. 2.1A). In mice,
matAbs are transferred to offspring both in utero and in milk (Hemmings and Morris,
1959; Jennewein et al., 2017). To verify that matAbs were transferred to the pups, we
collected serum from the mothers and pups at weaning (~21 days old) and measured
influenza virus-specific serum IgG titers by ELISA, reported as the ratio of offspring titer
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to corresponding maternal titer (Fig. 2.1B). Female mice efficiently transferred influenza
virus-specific antibodies to their pups, as most offspring:mother pairs had a ratio of ~1
(mean 1.03, range 0.65-1.81). After weaning, matAbs in the pups waned over time. The
serum influenza virus-specific titers of these pups became undetectable by HAI assays
by 38 days after birth (Fig 2.1C). Consistent with previous reports (Lee et al., 2016;
Malanchere et al., 1997), serum influenza virus-specific IgG decreased over time
following exponential decay with a half-life of 12±2 days (Fig 2.1D). Influenza virusspecific antibodies fell to background levels by ELISA by ~70-100 days after birth.
Maternal antibodies protect infant mice from influenza virus disease
Next, we tested whether influenza virus-specific matAbs could protect infant mice
from influenza virus infections. We intranasally infected 7 day old pups with or without
influenza virus-specific matAbs with 30 TCID50 PR8 virus. This dose of virus caused 80100% mortality in pups born to naïve mothers; however, pups inoculated in the presence
of influenza virus-specific matAbs were completely protected (Fig. 2.1E). We also
quantified viral titers in the lungs of pups 2 days post infection. We found high levels of
virus (~107 TCID50/g of tissue) in pups without influenza virus-specific matAbs, while we
were unable to detect virus in the lungs of pups with influenza virus-specific matAbs (Fig
2.1F). Taken together, these results show that influenza virus-specific matAbs are
efficiently transferred and protect infant mice from influenza disease.
Maternal antibodies inhibit de novo antibody responses to influenza virus infection and
conventional influenza vaccines
We next sought to determine the effect of matAbs on antibody responses elicited
by infection. We measured influenza virus-specific IgG titers in the sera of pups that
were intranasally infected with PR8 virus at 7 days of age in the presence or absence of
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influenza virus-specific matAbs. We used a dose of virus (3 TCID50 PR8) that was
sublethal for pups +/- influenza virus-specific matAbs for these experiments. At 125 dpi,
a timepoint at which matAbs have waned below the limit of detection (Fig. 2.1G, green
bar), influenza virus-specific serum IgG titers of mice inoculated with PR8 in the
presence of influenza virus-specific matAbs were equivalent to naïve mice (Fig. 2.1G,
blue and black bars). In contrast, influenza virus-specific serum IgG antibodies were
present at high levels in mice that were infected in the absence of matAbs (Fig. 2.1G,
red bar). Because maternally derived and de novo antibodies are indistinguishable when
the mother and pup are of the same strain, we confirmed that matAbs suppress de novo
antibody responses to influenza virus using a cross-fostering system. Murine matAbs are
efficiently transferred via milk (Hemmings and Morris, 1959; Jennewein et al., 2017) and
different strains of mice have differences in IgG subclasses (BALB/c, IgG2a; C57BL/6,
IgG2c). C57BL/6 pups born to unexposed mothers were nursed on exposed BALB/c
mothers, thus acquiring influenza virus-specific IgG2a matAbs via milk (Fig. 2.1H, left).
These C57BL/6 pups with IgG2a influenza virus-specific matAbs failed to mount de novo
IgG2c antibodies after influenza virus infection (Fig. 2.1H, right), confirming that matAbs
inhibit de novo antibody responses elicited by influenza virus infections. Therefore,
influenza virus-specific matAbs protect young mice from influenza virus infections but
prevent the induction of de novo influenza virus-specific antibody responses.
It is possible that antigen-specific matAbs inhibit de novo antibody responses
elicited by live virus infections by limiting virus replication and antigen production (Fig.
2.1F). It is unknown if matAbs similarly inhibit live attenuated influenza vaccines (LAIVs)
that require viral replication and inactivated influenza vaccines (IIVs) that do not require
viral replication. We intranasally infected mice with subclinical doses of PR8 virus to
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model LAIVs and we intramuscularly injected beta propriolactone (BPL)-inactivated
purified PR8 virus to model IIVs (Fig. 2.2A). Due to their size, we were not able to obtain
sufficient amounts of pre-vaccination sera from 7 day old pups and therefore all further
experiments were conducted on 21 day old juvenile mice. Consistent with experiments
with 7 day old mice, 21 day old mice receiving subclinical doses of live PR8 in the
absence of influenza virus-specific matAbs generated high serum Ab titers, while mice
exposed to live virus in the presence of influenza virus-specific matAbs did not (Fig.
2.2B). To determine if intranasal vaccinations early in life protect from infection in
adulthood in our model, we then challenged the same mice with 300 TCID50 PR8 virus at
189 days post vaccination (dpv), at which time residual matAbs had waned below the
protective threshold. Adult mice that were previously exposed in the absence of
influenza virus-specific matAbs were completely protected from infection whereas adult
mice that were previously exposed in the presence of influenza virus-specific matAbs
were susceptible (Fig 2.2C). We found similar results following intramuscular vaccination
of 21 day old mice with inactivated virus. Mice vaccinated with inactivated PR8 virus in
the presence of matAbs did not generate a de novo antibody response (Fig. 2.2D) and
were not protected during challenge (Fig. 2.2E). Thus, antigen-specific matAbs inhibit de
novo antibody responses after intranasal inoculation with live virus or intramuscular
vaccination with inactivated virus.
mRNA-LNP vaccination overcomes matAb inhibition of infant antibody responses
We and others recently demonstrated that nucleoside-modified mRNA-LNP
vaccines expressing HA elicited robust antibody responses in animal models and
humans (Bahl et al., 2017; Liang et al., 2017; Lindgren et al., 2017; Pardi et al., 2018a;
Pardi et al., 2018c). We found that mRNA-LNP are efficiently taken up by cells which
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then endogenously express high levels of antigen for more than 1 week (Pardi et al.,
2018a; Pardi et al., 2015). mRNA-LNP vaccination has several features that suggest it
may be able to circumvent matAb inhibition: (1) the vaccine itself does not include
antigen, precluding binding of antigen-specific matAbs to the vaccine; and (2) the
vaccine expresses antigens for long periods of time, which could be beneficial as
matAbs decline.
To determine if nucleoside-modified mRNA-LNP influenza vaccines can
circumvent antigen-specific matAbs, we intramuscularly injected 21 day old mice +/influenza virus-specific matAbs with 1 µg of mRNA-LNP vaccine encoding the
immunodominant surface glycoprotein hemagglutinin (HA) from PR8 virus. Unlike the
results following infection with live influenza virus and vaccination with conventional
vaccines, the PR8 HA mRNA-LNP vaccine elicited high levels of de novo influenza virusspecific antibodies in the presence of influenza virus-specific matAbs (Fig. 2.3A). PR8
HA mRNA-LNP-vaccinated mice (+/- matAbs) were fully protected when they were
subsequently challenged with PR8 virus in adulthood 189 dpv (Fig. 2.3B). mRNA-LNP
vaccines encoding either cell-associated or secreted HA elicited similarly high levels of
HA-specific antibodies in the presence of influenza virus-specific matAbs (Fig. 2.3C). To
test whether the protection after PR8 HA mRNA-LNP vaccination was antibodymediated, we passively transferred sera from vaccinated mice into naïve adult mice and
then challenged them with 300 TCID50 PR8 virus. Mice who received serum from the
control groups (mice who received PBS +/- matAbs) displayed severe disease, while
mice who received serum from mice vaccinated with PR8 HA mRNA-LNP in the
presence of matAbs were protected (Fig. 2.3D). The mRNA vaccine elicited equivalent
influenza virus-specific IgG1 antibodies +/- influenza virus-specific matAbs (Fig. 2.3E,
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left) but reduced IgG2a antibodies in the presence of matAbs (Fig. 2.3E, right). This
apparent shift towards a Th2 response in the presence of matAbs is interesting since
some studies suggest that Th2 responses are favored following immunizations with
immune complexes (Anderson et al., 2002; Anderson and Mosser, 2002).
mRNA-LNP vaccine elicits germinal center responses in the presence of matAbs
We previously found that nucleoside-modified mRNA-LNP vaccines elicit robust
germinal center reactions (Pardi et al., 2018a), which promote antibody class switching,
somatic hypermutation, and affinity maturation (Dufaud et al., 2017; Mesin et al., 2016).
We hypothesized that mRNA-LNP vaccines elicit protective responses in the presence
of antigen-specific matAbs by establishing robust long-lived germinal center reactions.
To address this, we measured HA-specific germinal center B cells (GCBs) by flow
cytometry (see gating strategy in Fig. 2.4) in the spleen and draining (popliteal) lymph
nodes of mice vaccinated intramuscularly with PR8 HA mRNA-LNP, poly(C) RNA-LNP
(negative control), or inactivated PR8 virus. As expected, mice vaccinated with poly(C)
RNA-LNP in the presence or absence of influenza virus-specific matAbs did not
generate HA-specific GCBs in the spleen (Fig. 2.5) or lymph nodes (Fig. 2.4). In the
absence of matAbs, inactivated influenza virus elicited a transient GCB response in the
spleen (Fig. 2.5) and a GCB response in the lymph node that was high at 14 dpv but
declined over time (Fig. 2.4). Consistent with the serum influenza virus-specific IgG titers
(Fig. 2.2C), matAbs inhibited GCB responses in mice vaccinated with inactivated
influenza virus in both the spleen and lymph nodes. In contrast, nucleoside-modified
PR8 HA mRNA-LNP elicited GCB responses in the presence and absence of influenza
virus-specific matAbs. In the absence of influenza virus-specific matAbs, PR8 HA
mRNA-LNP elicited a transient HA-specific GCB response in the spleen (Fig. 2.5) and
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persistent GC responses in lymph nodes that remained high at 56 dpv (Fig. 2.4). In the
presence of influenza virus-specific matAbs, PR8 HA mRNA-LNP failed to elicit GCBs in
the spleen (Fig. 2.5) and lymph node (Fig. 2.4) at 14 dpv; however, HA-specific GCBs
became elevated in the lymph nodes of these mice by 28 dpv and remained at high
levels by 56 dpv (Fig. 2.4). This suggests that nucleoside-modified mRNA-LNP vaccines
circumvent the inhibitory effects of matAbs by establishing sustained germinal center
reactions that are required for the induction of robust de novo antibody responses.
Discussion
It is currently unclear why nucleoside-modified mRNA-LNP vaccines are so
efficient at establishing germinal centers in adult (Pardi et al., 2018a) and young mice
(Fig. 2.4). It is possible that this is due to prolonged antigen expression from mRNA-LNP
vaccines (Pardi et al., 2018a; Pardi et al., 2015). Several studies have demonstrated that
prolonged antigen availability leads to stronger GC responses (reviewed in (Cirelli and
Crotty, 2017)). It is also unclear why mRNA-elicited de novo antibody responses are
skewed towards Th2 in the presence of antigen-specific matAbs (Fig. 2.3D). This may
be due to immune complex formation (Anderson et al., 2002; Anderson and Mosser,
2002), lower overall amounts of antigen (Tubo and Jenkins, 2014; van Panhuys, 2016),
or priming in distinct immunological sites (Fig. 2.4, 2.5). Future studies should directly
compare how matAbs differentially affect mRNA-LNP vaccines and other genetic
vaccines, such as DNA vaccines, which have had variable success in the presence of
matAbs (Chen et al., 2007; Hassett et al., 1997; Manickan et al., 1997; Monteil et al.,
1996; Pertmer et al., 2000; Siegrist et al., 1998). It is unclear why nucleoside-modified
mRNA-LNP vaccines expressing HA (Fig. 2.3), but not DNA vaccines expressing HA
(Chen et al., 2007; Pertmer et al., 2000), are able to elicit protective antibody responses
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in the presence of influenza virus-specific matAbs. This might be due to differences in
levels and duration of antigen expression or due to unique properties of mRNA vaccines.
Our studies suggest that nucleoside-modified mRNA-LNP vaccines are an
attractive candidate for use in young children. Children under 6 months of age remain at
increased risk of severe disease from viral and bacterial infections, yet many currently
available vaccines are not licensed for this age group (Hodgins and Shewen, 2012).
While maternal vaccination can provide passive protection, it also negatively impacts the
infant’s own active immunity. Nucleoside-modified mRNA-LNP vaccines offer a
promising strategy to vaccinate this vulnerable population because they can elicit
antibody responses in the presence of antigen-specific matAbs. Because the mRNALNP platform is easily adaptable to different antigens (Pardi et al., 2018b), this system
could offer a general solution to matAb inhibition of responses to current vaccines.
Materials and Methods
Mouse model
Experiments involving mice complied with all relevant ethical regulations. All protocols
involving mice were approved by the Institutional Animal Care and Use Committee of the
Wistar Institute and the University of Pennsylvania. BALB/c and C57BL/6 mice were
purchased from Charles River Laboratories or bred in-house. 6-8 week old female mice
were intranasally infected with 20 TCID50 A/Puerto Rico/8/1934 (H1N1) (PR8) virus
under isoflurane anesthesia. After 3 weeks, serum was collected and antibody titers
were measured by HAI. At least 3 weeks post infection, exposed female mice and
unexposed controls were mated with males of the same strain and allowed to have
pups. Pups were either infected at ~7 days old (range 6-8 days), or infected or
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vaccinated at ~21 days old (range 19-23 days). Pups were weaned at ~21 days old
(range 19-23 days). For cross-fostering experiments, 1 day old C57BL/6 pups were
removed from their naïve mothers and fostered with lactating influenza virus-exposed
BALB/c females. Both male and female pups were used in experiments. In experiments
involving infection of 7 day old pups, all pups within each litter received the same
treatment to prevent transmission of virus from infected to uninfected pups. In
experiments involving infection or vaccination of 21 day old pups, pups of each sex and
litter were randomized to treatment groups. The number of pups in each experiment
varied due to litter size.
Serum collection
Blood was collected at the indicated timepoints by submandibular puncture into 1.1 ml ZGel tubes (Sarstedt) using a 5mm lancet (Medipoint). Sera were heat treated at 55°C for
30 minutes and stored at 4°C.
Infections and Vaccinations
All intranasal infections were performed under isoflurane anesthesia. Virus was diluted in
PBS and instilled into the nostrils in 50 µl (adults), 25 µl (21 day old mice) or 5 µl
(neonates). 7 day old mice were infected with 3 or 30 TCID50 PR8 virus. 21 day old mice
were infected with 10 TCID50. Adult mice were challenged with 300 TCID50. After
challenge, mice were monitored at least 1x daily and were euthanized when they
became lethargic, cachexic, or unresponsive to stimuli. For intramuscular (i.m.)
injections, virus or vaccine was diluted in PBS and injected into the lower or upper hind
leg in 50 µl per leg.
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Viruses
A/Puerto Rico/8/1934 (H1N1) (PR8) virus was propagated in 10 day old fertilized
chicken eggs. Allantoic fluid was clarified and aliquoted, and titer was determined by
TCID50 on Madin-Darby canine kidney (MDCK) cells. For inactivated virus vaccine,
allantoic fluid was purified by sucrose gradient ultracentrifugation and inactivated with
0.1% beta propriolactone (BPL) with 0.1 M HEPES. Titer for inactivated virus was
determined by hemagglutination unit (HAU) assay.
mRNA production
mRNAs were produced as previously described (Pardi et al., 2013) using T7 RNA
polymerase (Megascript, Ambion) on linearized plasmids encoding codon-optimized
(Thess et al., 2015) A/Puerto Rico/8/1934 influenza virus HA (pTEV-PR8 HA-A101 and
pTEV-sPR8 HA-A101). For some experiments, we used mRNA constructs producing
secreted HA. For mRNA producing secreted HA, the transmembrane and cytoplasmic
domains of HA were removed and replaced with a codon-optimized sequence for the
trimerization domain (foldon; amino acid sequence
GSGYIPEAPRDGQAYVRKDGEWVLLSTFL) (Frank et al., 2001; Stevens et al., 2006;
Whittle et al., 2014). mRNAs were transcribed to contain 101 nucleotide-long poly(A)
tails. One-methylpseudouridine (m1Ψ)-5’-triphosphate (TriLink) instead of UTP was used
to generate modified nucleoside-containing mRNA. RNAs were capped using the m7G
capping kit with 2’-O-methyltransferase (ScriptCap, CellScript) to obtain cap1. mRNA
was purified by Fast Protein Liquid Chromatography (FPLC) (Akta Purifier, GE
Healthcare), as described (Weissman et al., 2013). All mRNAs were analyzed by
denaturing or native agarose gel electrophoresis and were stored frozen at -20°C.
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LNP formulation of the mRNA
FPLC-purified m1Ψ-containing RNAs were encapsulated in LNP using a self-assembly
process as previously described (Pardi et al., 2015) wherein an ethanolic lipid mixture of
ionizable cationic lipid, phosphatidylcholine, cholesterol and PEG-lipid was rapidly mixed
with an aqueous solution containing mRNA at acidic pH. The RNA-loaded particles were
characterized and subsequently stored at -80°C at a concentration of 1 µg/µl. The mean
hydrodynamic diameter of these mRNA-LNP was ~80 nm with a polydispersity index of
0.02-0.06 and an encapsulation efficiency of ~95%.
Viral titer measurements
Pups were intranasally inoculated at 7 days old with 30 TCID50 PR8 virus. 2 days later,
mice were euthanized by decapitation with a sharp blade under isoflurane anesthesia
and the lungs were removed. Viral titers in lung homogenates were quantified by TCID50
assay using MDCK cells (using the Reed & Muench calculator).
Passive transfer
Sera were pooled and 500 µl was injected intraperitoneally into naïve 6-8 week old
female BALB/c mice. 4-5 hours later, sera were collected to assure efficient passive
transfer and mice were intranasally challenged with 300 TCID50 PR8 virus under
anesthesia. After challenge, mice were monitored at least 1x daily and were euthanized
when they became lethargic, cachexic, or unresponsive to stimuli. Transfer of antibodies
was verified by ELISA.
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Cells
Madin-Darby canine kidney (MDCK) cells were maintained in modified Eagle’s medium
(MEM; Mediatech) with 10% fetal bovine serum (FBS; Sigma). 293T cells were
maintained in Dulbecco’s MEM (DMEM; Mediatech) with 10% FBS.
ELISA
Immulon 4HBX plates (Thermo Scientific) were coated with 0.4 HAU/µl BPL-inactivated
PR8 allantoic fluid diluted in PBS overnight at 4°C. Plates were blocked with 3% bovine
serum albumin (BSA; Sigma) in PBS for 2h at room temperature, then washed with
distilled water. Primary antibodies or sera were diluted in 1% BSA in PBS and incubated
in the plates for 2h at room temperature. Plates were washed and secondary antibody
(goat anti-mouse IgG, IgG1, or IgG2a, human-adsorbed, conjugated to alkaline
phosphatase, Southern Biotech) was diluted 1:1000 in 1% BSA in PBS and incubated in
the plates for 1h at room temperature. Plates were washed and developed with 1mg/ml
p-nitrophenyl phosphate (PNPP) for 1h at room temperature and read on a SpectraMAX
190 (Molecular Devices).
HAU
Virus was 2-fold serially diluted in a volume of 50 µl across a 96 well polystyrene U
bottom plate (Falcon) and incubated for 45 minutes at room temperature with 12.5 µl of
2% (vol/vol) washed turkey erythrocytes (Lampire) in PBS.
HAI
Sera were serially diluted 2-fold in PBS in a 96 well polystyrene U bottom plate (Falcon)
and mixed with 4 agglutinating doses of virus in a total volume of 100 µl. 12.5ul of 2%
(vol/vol) washed turkey erythrocytes (Lampire) in PBS were added. Agglutination was
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read out after 45 minutes at room temperature. HAI titers are expressed as the highest
dilution of serum that inhibited 4 agglutinating doses of virus. Titers <10 were not
detectable.
Flow cytometry
At the specified time post-vaccination, mice were euthanized by CO2 inhalation and
spleens and draining lymph nodes were collected and stored on ice. Organs were
quickly processed into single cell suspensions in 5% RPMI medium. Spleen samples
were treated with ACK lysing buffer (Thermo Fisher). Dead cells were stained with
Zombie Aqua Fixable Viability Kit (Biolegend). Fc receptors were blocked with antimouse CD16/CD32 (Mouse Fc Block, BD). Cells were stained with the following
antibodies/reagents: anti-CD19-BV785 (clone 6D5, Biolegend), anti-B220-PE-dazzle
(clone RA3-6B2, Biolegend), anti-CD38-AF700 (clone 90, eBioscience), PNA-FITC
(Vector Labs), anti-CD138-BV421 (clone 281-2, Biolegend), anti-IgD-APC-Cy7 (clone
11-26c.2a, Biolegend), anti-CD4-PE-Cy7 (clone RM4-5, eBioscience), anti-CD8-PE-Cy7
(clone 53-6.7, eBioscience), anti-F4/80-PE-Cy7 (clone BM8, eBioscience), anti-Ter119PE-Cy7 (clone TER-119, eBioscience). To identify HA-specific B cells, cells were stained
with PR8 HA protein with a Y98F mutation in the receptor binding site, which prevents
nonspecific binding to sialic acid (Whittle et al., 2014), conjugated to PE. Singly-stained
Ig κ compensation microparticles (BD) or cells were used to determine appropriate
compensation settings for each experiment. Events were acquired on an LSRII flow
cytometer (BD). Data were analyzed with FlowJo software (FlowJo, LLC). Gating
strategy is shown in Fig. 2.4.
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Statistics
Data were graphed and analyzed using GraphPad Prism 7 (GraphPad). Titer and weight
data are graphed as mean +/- SD. Survival data were analyzed by log-rank test.
Timecourse data were analyzed by one-way ANOVA with Tukey’s post-test at each
timepoint. Viral titers in the lungs were analyzed by two-tailed Welch’s t test. IgG subtype
titers were analyzed by two-tailed t-test. Germinal center B cell responses were
analyzed by one-way ANOVA with Dunnett’s post-test, comparing 4 and 8 weeks to 2
weeks post vaccination. Titers against cell-associated and secreted PR8 HA mRNA-LNP
were compared by one-way ANOVA with Sidak’s post-test.

38

Figures
Figure 2.1

Figure 2.1. MatAbs protect infant mice from influenza disease but inhibit de novo
antibody responses.
A, Experimental design is shown. B, Serum was collected from mothers and pups on the
day of weaning and influenza virus-specific IgG titers were measured by ELISA.
Pup:mother titer ratios are shown. Each point represents one litter (1-10 pups/litter,
mean=5.3). C-D, Serum was collected at the indicated timepoints from pups who
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received influenza virus-specific matAbs and (C) hemagglutination inhibition (HAI) and
(D) influenza virus-specific ELISA titers were measured. ND, not detected. One-phase
decay (R2>0.97 for each mouse) was fitted to titer data in (D); each line represents one
mouse. n=6 mice. E-F, 7 day old mice +/-matAbs were inoculated with 30 TCID50 PR8
virus i.n. E, Survival was measured over 14 days post inoculation. n=3 (+matAbs) or 5 (matAbs) mice per group. p=0.008, log-rank test. F, Viral titers in the lungs were
measured 2 days post inoculation. Each point represents 1 mouse. n=4 (+matAbs) or 5
(-matAbs) mice per group. p<0.0001, two-tailed Welch’s t test. G, Serum influenza virusspecific IgG was measured by ELISA 125 days post i.n. inoculation +/-matAbs. n=6 (matAbs), 8 (+matAbs/virus), or 9 (+matAbs/PBS) mice per group. Groups were
compared using one-way ANOVA with Tukey’s post-test. H, C57BL/6 pups born to
unexposed mothers were fostered with exposed BALB/c mothers and then inoculated
with 3 TCID50 PR8 virus or PBS i.n. at 7 days old. Serum influenza virus-specific IgG2a
(maternal) or IgG2c (de novo) was measured by ELISA 14 days post inoculation. n=3 (matAbs/virus and +matAbs/PBS) or 6 (+matAbs/virus) mice per group. Groups were
compared using one-way ANOVA with Tukey’s post-test. Data in B, C, F, G, H are
shown as mean +/- SD. C-G are representative of 3 independent experiments and H is
representative of 2 independent experiments. ns, not significant.
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Figure 2.2

Figure 2.2. MatAbs inhibit antibody responses to conventional influenza vaccines.
A, Experimental design is shown. B,D, 21 day old mice +/- matAbs were inoculated with
10 TCID50 PR8 virus i.n. (B) or 1000 HAU purified inactivated PR8 virus i.m. (D) or PBS,
and influenza virus-specific antibody responses were measured over time. * denotes
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p<0.05 after comparison of titer of sera from mice exposed to influenza virus versus PBS
in the presence (blue *) or absence (red *) of influenza virus-specific matAbs, one-way
ANOVA with Tukey’s post-test at each timepoint. ns, not significant. C,E, Mice
inoculated in B,D were challenged at 189 or 194 days post-vaccination with 300 TCID50
PR8 virus i.n. and weight loss was measured over 14 days. * denotes p<0.05 after
comparison of % baseline weight post-challenge of mice exposed to influenza virus
versus PBS as infants in the presence (blue *) or absence (red *) of influenza virusspecific matAbs, one-way ANOVA with Tukey’s post-test at each day. ns, not significant.
In E, one mouse survived in the +matAbs/+influenza virus exposure group. n=5
(+matAbs/vaccine), 6 (+matAbs/PBS), or 7 (-matAbs) mice per group (B, C); 3 (naïve), 4
(+matAbs/vaccine and -matAbs/vaccine), or 11 (+matAbs/PBS) mice per group (D, E).
Data in B-E are shown as mean +/- SD. B, C are representative of 3 independent
experiments. D, E are representative of 2 independent experiments.
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Figure 2.3

Figure 2.3. Nucleoside-modified PR8 HA mRNA-LNP vaccine elicits protective Ab
responses in the presence of matAbs.
A, 21 day old mice were vaccinated i.m. with 1 µg nucleoside-modified PR8 HA mRNALNP and influenza virus-specific serum antibody responses were measured by ELISA. *
denotes p<0.05 after comparison of titer of sera from mice vaccinated with PR8 HA
mRNA-LNP versus PBS in the presence (blue *) or absence (red *) of influenza virusspecific matAbs, one-way ANOVA with Tukey’s post-test at each timepoint. B, Mice in
(A) were challenged at 189 days post vaccination with 300 TCID50 PR8 virus i.n. and
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weight loss was measured over 14 days. * denotes p<0.05 after comparison of %
baseline weight post-challenge of mice vaccinated as infants with PR8 HA mRNA-LNP
versus PBS in the presence (blue *) or absence (red *) of influenza virus-specific
matAbs, one-way ANOVA with Tukey’s post-test at each day. A-B, n=3 (+matAbs) or 4 (matAbs) mice per group. C, 21 day old mice were vaccinated with cell-associated (C) or
secreted (S) PR8 HA mRNA-LNP or PBS (-) in the presence or absence of influenza
virus-specific matAbs. For the secreted construct, the transmembrane (TM) and
cytoplasmic domains were removed and a trimerization domain was introduced. Serum
was collected 70 days post-vaccination and influenza virus-specific IgG was measured
by ELISA. n=4 (-matAbs/C vaccine and -matAbs/S vaccine), 5 (naïve), 10
(+matAbs/PBS), 18 (+matAbs/C vaccine), or 19 (+matAbs/S vaccine) mice per group.
Each point represents 1 mouse. Data are shown as mean +/- SD. Titers were compared
by one-way ANOVA with Sidak’s post-test. ns, not significant. D, Serum was collected at
100+ days post-vaccination with 1 µg PR8 HA mRNA-LNP or PBS +/-matAbs and
pooled. 500 µl pooled serum was transferred i.p. to 6-8 week old naïve mice and 4-5
hours later, mice were challenged with 300 TCID50 PR8 virus i.n. Weight loss was
measured over 14 days. n=4 mice per group. * denotes p<0.05 after comparison of %
baseline weight post challenge of mice that received sera from mice vaccinated with
PR8 HA mRNA-LNP versus PBS as infants in the presence of influenza virus-specific
matAbs, one-way ANOVA with Tukey’s post-test at each day. E, Sera from mice
vaccinated with 1 µg PR8 HA LNP +/-matAbs and naïve mice were collected 189 days
post-vaccination and analyzed for influenza virus-specific IgG1 (left) or IgG2a (right). n=8
(+matAbs/vaccine), 9 (-matAbs/vaccine) or 4 (naïve) mice per group. Serum titers of
mice vaccinated with PR8 HA mRNA-LNP +/-matAbs were compared with an unpaired
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two-tailed t test. In E, each point represents 1 mouse. Data are shown as mean +/- SD.
A-E are representative of 2 independent experiments.
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Figure 2.4

Figure 2.4. Nucleoside-modified PR8 HA mRNA-LNP vaccine elicits prolonged HAspecific GC B cell response in the presence of matAbs.
(A) Flow cytometry gating strategy for HA+ GCB cells. (B) Mice were vaccinated with 1
µg nucleoside-modified PR8 HA mRNA-LNP, 1000 HAU inactivated PR8 virus, or 1 µg
poly(C) RNA-LNP i.m. at 21 days of age. Draining (popliteal) lymph nodes were
collected and HA-specific germinal center B cells (HA probe+ CD19+ B220+ CD138PNA+ CD38-) were analyzed by flow cytometry. Data are pooled from 3 independent
experiments (n=4 (-matAbs) or 5 (+matAbs) mice per group per experiment) at each
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time point. Each point represents 1 mouse. Line represents mean. 4 and 8 week postvaccination timepoints within each condition were compared to the 2 week postvaccination timepoint by one-way ANOVA with Dunnett’s post-test.
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Figure 2.5

Figure 2.5. Nucleoside-modified PR8 HA mRNA-LNP vaccine elicits transient
germinal center response in the spleen in the absence of influenza virus-specific
matAbs.
Mice were vaccinated with 1 µg PR8 HA mRNA-LNP, 1000HAU inactivated PR8 virus,
or 1 µg poly(C) RNA-LNP i.m. at 21 days of age. Spleens were collected at the specified
timepoints and PR8 HA-specific germinal center B cells (HA probe+ CD19+ B220+
CD138- PNA+ CD38-) were analyzed by flow cytometry. Data are pooled from 3
independent experiments (n=4 (-matAbs) or 5 (+matAbs) mice per group per
experiment) at each timepoint. Each point represents 1 mouse. Line represents mean. 4
and 8 week post-vaccination timepoints within each condition were compared to the 2
weeks post-vaccination timepoint by one-way ANOVA with Dunnett’s post-test.

48

CHAPTER 3: THE EFFECT OF FLAVIVIRUS-SPECIFIC MATERNAL ANTIBODIES
ON ZIKA VIRUS INFECTION OF INFANT MICE
Parts of this chapter have been previously published as:
Willis, E. and Hensley, S. E. (2017). Characterization of Zika virus binding and
enhancement potential of a large panel of flavivirus murine monoclonal antibodies.
Virology. 2017 Aug;508:1-6.

Summary
Zika virus (ZIKV) recently became a public health concern due to its newly recognized
association with neurological disease in adults and microcephaly and other congenital
defects in infants born to women infected during pregnancy. One possible explanation
for the emergence of severe disease during the most recent epidemic is that the virus
entered a population with distinct flavivirus exposures. Previous flavivirus exposure can
exacerbate disease during infection with a heterologous virus, a process termed
antibody-dependent enhancement (ADE). Thus we hypothesized that previous exposure
to flaviviruses could enhance ZIKV disease. In this chapter, we find that several West
Nile virus (WNV)- or dengue virus (DENV)-specific monoclonal antibodies enhance ZIKV
replication in vitro. We then adapt our mouse model from chapter two to investigate
whether flavivirus-specific matAbs enhance disease in infant mice infected with ZIKV.
We find that DENV-specific matAbs do not affect the course of ZIKV disease, but ZIKVspecific matAbs protect infant mice. These findings have important implications for the
development of flavivirus-specific vaccines for use in pregnant women and infants.
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Introduction
It is unclear why neurological symptoms have not been linked to ZIKV infections
prior to 2013. It is possible that this is due to underreporting, or that contemporary ZIKV
strains have acquired genetic changes that alter disease progression. Alternatively, the
host populations most affected by the current ZIKV outbreak may be more pre-disposed
to develop ZIKV-elicited neurological disease compared to host populations affected by
earlier ZIKV outbreaks.
How can different host populations have different susceptibility to ZIKV-elicited
severe disease? One possibility is that host populations affected by past and current
ZIKV outbreaks have different immune histories. ZIKV emerged recently into areas with
complex patterns of pre-existing anti-flavivirus immunity. Prior flavivirus exposures can
enhance disease caused by infections with antigenically distinct flaviviruses, a process
termed antibody-dependent enhancement (ADE). ADE is thought to occur when immune
complexes, formed between cross-reactive antibodies and virus, are targeted to Fc
receptor-bearing cells that are permissive for viral replication, leading to increased viral
load (Halstead, 2015; Schmid et al., 2014; Whitehead et al., 2007). ADE may also occur
in individuals who make antibodies that more effectively bind activating Fc receptors
(Wang et al., 2017).
ADE of DENV infection by heterologous DENV antibodies has been shown in
vitro and in animal models (Halstead, 2003, 2015). Epidemiological evidence of ADE in
human DENV infections arises from (1) the observation that the highest incidence of
severe disease occurs in 4-8 month old children, coinciding with the waning of maternal
antibodies (matAbs) (Chau et al., 2008; Halstead, 1970; Halstead et al., 2002; Kliks et
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al., 1988) and (2) a longitudinal cohort study that defined a narrow range of pre-existing
DENV titers associated with the highest risk of severe disease (Katzelnick et al., 2017).
Enhancement of ZIKV infection by pre-existing DENV antibodies is an attractive
explanation for the severe disease manifestations observed in the recent ZIKV epidemic.
Despite vigorous study, whether pre-existing DENV-specific antibodies can enhance
ZIKV infection or disease in vivo remains controversial. One study demonstrated ADE of
ZIKV infection in Stat2-/- mice after passive transfer of DENV- or WNV-specific human
plasma (Bardina et al., 2017), but DENV pre-exposure did not enhance disease in
monkeys (McCracken et al., 2017). Two groups have investigated this question in the
context of maternal/fetal infections. A pre-print mouse study suggested that DENV preexposure may lead to adverse fetal outcomes after ZIKV infection during pregnancy
(Rathore et al., 2018), but a human epidemiological study found no association between
maternal DENV pre-exposure and birth outcomes (Halai et al., 2017). Two important
confounding factors that may explain this discrepancy are the differences in placentation
and route of antibody transfer in murine versus human pregnancies, both of which may
impact viral access to and inflammation of the placenta and fetus (Carter, 2007;
Roopenian and Akilesh, 2007). Here, we use of post-natal ZIKV infection of infant mice
in the presence of matAbs to isolate the effect of flavivirus-specific antibodies on ZIKV
pathogenesis. DENV-specific matAbs have been shown to enhance heterologous DENV
disease in mouse models (Lee et al., 2016; Martinez Gomez et al., 2016; Ng et al.,
2014). Although ZIKV was found to infect the central nervous system in neonatal mice
(Huang et al., 2016; Li et al., 2018; Yu et al., 2017a; Zhang et al., 2017), the effect of
matAbs on post-natal ZIKV infection and disease has not been investigated.
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In this chapter, we test the hypothesis that DENV-specific matAbs enhance ZIKV
disease in infant mice. First we examine the enhancing potential of a panel of
monoclonal antibodies elicited by other flaviviruses in vitro. We then pre-expose female
mice to DENV and ZIKV and subsequently infect their pups with ZIKV to ask whether
flavivirus-specific matAbs exacerbate ZIKV disease.
Results
mAbs elicited by DENV and WNV bind to ZIKV
We obtained a large panel of mouse mAbs elicited by DENV and WNV antigens
from BEI Resources (Table 3.1), most of which were created by Michael Diamond
(Washington University) and colleagues (Brien et al., 2010; Gentry et al., 1982; Henchal
et al., 1982; Oliphant et al., 2005; Oliphant et al., 2006; Shrestha et al., 2010; SukupolviPetty et al., 2013). These mAbs include 20 mAbs elicited by DENV serotype 1 (DENV1), 2 mAbs elicited by DENV-2, 14 mAbs elicited by DENV-3, 11 mAbs elicited by
DENV-4, and 7 mAbs elicited by WNV. This panel of mAbs includes 33 IgG1, 14 IgG2a,
5 IgG2b, and 2 IgG2c. All of the mAbs bind the envelope (E) protein of the respective
eliciting antigen, and most bind to domains I/II (DI/II) (n=24 mAbs) or DIII (n=26 mAbs) of
the E protein (Fig. 3.1).
First, we used conventional ELISAs to measure binding of each mAb to a
contemporary strain of ZIKV isolated from Puerto Rico in 2015 (PRVABC59) (Fig. 3.2).
We considered a mAb to be ZIKV-reactive if the ZIKV ELISA signal was >2x the ELISA
signal of the mAb against a no-antigen control and of an irrelevant influenza virusspecific mAb (170-3C12) against PRVABC59 ZIKV in three independent experiments.
Six of 49 DENV-elicited and 2 of 7 WNV-elicited mAbs were considered ZIKV-reactive
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using these criteria. We also included a ZIKV-specific mAb (ZIKV-0402166) as a control.
Interestingly, several of the DENV- or WNV-specific mAbs bound to ZIKV more strongly
than the ZIKV-0402166 mAb.
Next, we used flow cytometry to measure binding of these 8 cross-reactive mAbs
to ZIKV-infected Vero cells. All of the Abs that bound to ZIKV by ELISA also bound to
infected cells (Fig. 3.3). Three of the mAbs (4G2, WNV-E18, and WNV-E24) showed
relatively high variance in binding to infected Veros (see wider range of fluorescence
intensities in Fig. 3.3). This binding pattern suggests that the epitopes of these mAbs are
variably present 24 hours post-infection. This may be related to viral breathing of
immature virions, heterogeneity in the viral population, or different stages of maturity of
the viral particle within individual cells (Diamond and Pierson, 2015). It is also possible
that this might relate to heterogeneity in the mAb preparations or differential reactivity of
the anti-mouse IgG secondary Ab used in these experiments.
DENV- and WNV-elicited mAbs enhance ZIKV infection in vitro
Previous studies suggest that some DENV-elicited mAbs can inhibit ZIKV
replication (Barba-Spaeth et al., 2016; Priyamvada et al., 2016), while other DENVelicited mAbs enhance ZIKV infection of Fc receptor-bearing cells (Charles and
Christofferson, 2016; Dejnirattisai et al., 2016; Paul et al., 2016; Priyamvada et al., 2016;
Stettler et al., 2016; Zhao et al., 2016). To determine whether the 8 cross-reactive mAbs
in our study were able to neutralize ZIKV in vitro, we completed focus reduction
neutralization tests (FRNTs) which assess the ability of Abs to block infection of Vero
cells, which do not express Fc receptors. None of the 8 cross-reactive mAbs were able
to neutralize ZIKV infection of Vero cells at concentrations up to 10 µg/ml (Fig. 3.4A). In
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contrast, as a positive control, we found that sera collected from ZIKV-infected mice
were able to neutralize ZIKV in these assays (Fig. 3.4A).
We next completed similar experiments in K562 cells, which are a human
erythroleukemic cell line that express Fc receptors. We infected K562 cells +/- each mAb
and then used flow cytometry to measure ZIKV E protein expression 3 days later.
Infection in the presence of both WNV-elicited mAbs, as well as 4G2, increased the
percentage of K562 cells expressing ZIKV E protein (Fig. 3.4B). The 3 mAbs that
enhanced infection of K562 cells are IgG2a isotype, while the non-enhancing mAbs are
mostly IgG1 (and one IgG2b). In mice, IgG2a mAbs have been associated with ADE
(Halstead, 2003); however, in this in vitro system utilizing a human cell line, the
predominance of IgG2a enhancing mAbs is likely due to the higher affinity of murine
IgG2a than IgG1 or IgG2b for human Fc receptors (Lubeck et al., 1985). There was not
a strict correlation between mAb relative binding and enhancement (Fig. 3.4C). Notably,
the 3 mAbs that enhanced infection of K562 cells are the same mAbs that displayed
higher variance in binding to infected Vero cells (Fig. 3.3).
Female Ifnar1-/- mice transfer flavivrus-specific matAbs to infant mice
The in vitro data suggest that antibodies elicited by different flavivirus exposures
and of different specificities can enhance ZIKV infection in vitro. We next wanted to test
whether flavivirus-specific matAbs contribute to disease in vivo. To investigate whether
matAbs affect the course of ZIKV disease in infant mice, we modified our mouse model
described in chapter two. ZIKV does not efficiently infect wild-type mice because the
virus cannot antagonize murine innate immune pathways; however, mice deficient in the
interferon α/β receptor 1 (Ifnar1-/- mice) are susceptible to ZIKV infection and disease
(Lazear et al., 2016; Tripathi et al., 2017). We exposed two groups of naïve female
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Ifnar1-/- mice to ZIKV PRVABC59 or DENV New Guinea C, a DENV-2 strain, by
intravenous (i.v.) injection. We intradermally (i.d.) immunized a third group with an
mRNA-LNP vaccine encoding ZIKV surface proteins prM and E. This ZIKV prM-E
mRNA-LNP vaccine (Pardi et al., 2017) and a similar vaccine (Richner et al., 2017a)
were previously demonstrated to protect adult animals from ZIKV infection. A fourth
group of female mice remained naïve. Two weeks later, we collected serum from these
mice and confirmed their anti-DENV and -ZIKV serum antibody titers by ELISA. Adult
female Ifnar1-/- mice infected with DENV or ZIKV or vaccinated with prM-E mRNA-LNP
developed antibody responses (Fig. 3.5A). Antibody responses were cross-reactive
between DENV and ZIKV although the antibody titer against the homologous virus was
higher than the titer against the heterologous virus in each case.
Next, we mated flavivirus-exposed and naïve females with naïve male Ifnar1-/mice and allowed them to deliver their pups. At 3 weeks old, we collected serum from
the infant mice and measured their serum anti-DENV and -ZIKV antibody titers to
quantify matAb transfer from mother to infants. All infant mice born to pre-exposed
females had flavivirus-specific serum antibodies (Fig. 3.5B). MatAbs were transferred
efficiently, with the ratio of antibody titer in the pups:mother’s sera at 0.78. Interestingly,
the efficiency of transfer was lower for cross-reactive antibodies from DENV-exposed
females, but not ZIKV-exposed females. This may suggest selective specificity or avidity
of transferred antibodies.
ZIKV matAbs protect infant mice from ZIKV disease
To determine whether matAbs protect from or enhance ZIKV disease in infant
mice, we challenged infant mice with 20 PFU ZIKV in the presence or absence of
flavivirus-specific matAbs and either monitored the clinical course of disease or
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measured viral loads in tissues. We recorded the weight and clinical signs of each
mouse daily. Weight is expressed as percentage of baseline (day of challenge) weight.
Uninfected control mice (Fig 3.6A,B, gray) gained weight over this time period. Mice
infected with ZIKV in the absence of matAbs (Fig 3.6A,B, black) gained weight until 4
days post challenge, then lost weight until day 9-10 post challenge, and then began to
recover. Mice infected in the presence of ZIKV-specific matAbs, born to mothers infected
with ZIKV (Fig 3.6A,B, blue) or vaccinated with prM-E mRNA-LNP (Fig 3.6A,B, green),
were fully protected from weight loss during challenge. In contrast, mice infected with
ZIKV in the presence of DENV-specific matAbs (Fig 3.6A,B, red) displayed weight loss
identical to mice infected in the absence of matAbs (black). The pre-infection ZIKVspecific matAb titer correlated positively with the pup’s percentage of baseline weight at
10 days post challenge (Fig. 3.6C), suggesting that matAbs above a certain threshold
protect mice from ZIKV disease.
We also monitored clinical disease in infant mice infected with ZIKV. We
observed mice daily and assigned each mouse a clinical score based on the system
shown in Table 3.2. Mice with clinical score 5 or 6 were euthanized. Mice infected with
ZIKV in the absence of matAbs or in the presence of DENV-specific matAbs (Fig 3.6D,E,
black and red) displayed clinical signs ranging from mild (e.g. weakness) to severe (e.g.
limb paralysis; central nervous system deficits requiring euthanasia). The maximum
clinical score for each pup was inversely correlated with the pre-challenge ZIKV-specific
matAb titer (Fig. 3.6F). Mice with ZIKV-specific matAbs and uninfected mice did not
display any clinical signs (Fig 3.6D,E, blue, green, and gray). Survival of ZIKV-infected
mice post-challenge is consistent with the weight loss and clinical score data (Fig. 3.6G).
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To further investigate matAb-mediated protection of infant mice, we measured
viral loads 6 days post challenge by qPCR (Fig. 3.7). In the sera, spleens, and testes,
most mice infected in the presence of DENV-specific matAbs had similar viral loads to
mice infected in the absence of flavivirus-specific matAbs. However, mice infected in the
presence of ZIKV-specific matAbs had greatly reduced viral RNA in all of the organs
tested. Together with the clinical disease data, these results show that ZIKV-specific
matAbs protect infant mice from ZIKV disease, while DENV-specific matAbs neither
protect from nor enhance ZIKV disease.
Discussion
In this chapter, we showed that antibodies elicited by related flaviviruses can
enhance ZIKV infection of permissive cells in vitro. We further investigated this finding in
vivo and found that DENV-specific matAbs do not affect the course of ZIKV disease in
infant mice; however, ZIKV-specific matAbs elicited by maternal infection or mRNA-LNP
vaccination can protect infant mice.
Several recent studies have demonstrated that DENV-specific mAbs or DENVelicited polyclonal sera can enhance ZIKV infection in vitro (Charles and Christofferson,
2016; Dejnirattisai et al., 2016; Paul et al., 2016; Stettler et al., 2016; Zhao et al., 2016)
and a recent study demonstrated that DENV and WNV-elicited Abs can enhance ZIKV
infection in vivo (Bardina et al., 2017). In the current study, we tested ZIKV binding and
enhancing potential of a large panel of murine flavivirus mAbs and we identified mAbs
elicited by DENV and WNV antigens that are capable of enhancing ZIKV infection in
vitro. All enhancing mAbs were of the IgG2a subclass and displayed similar binding
patterns as determined by flow cytometry.
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The ZIKV E protein is closely related to DENV E proteins (54-57% amino acid
conservation) and the WNV E protein (53% amino acid conservation) (Barba-Spaeth et
al., 2016). One of the 3 enhancing mAbs (4G2) in our studies was elicited by DENV.
DENVs are prevalent in Brazil and other areas of the world that have been greatly
affected by the current ZIKV outbreak (Messina et al., 2014). It is interesting that 2 of 3
enhancing mAbs identified in our studies were elicited by WNV. Zhao et al. also
observed in vitro enhancement of ZIKV infection by a mAb elicited by WNV (Zhao et al.,
2016). WNV has been reported in northeastern regions of Brazil (Vieira et al., 2015) that
have had high levels of ZIKV-associated microcephaly (Brasil et al., 2016; Hazin et al.,
2016; Mlakar et al., 2016). Interestingly, a study in mice reported that previous ZIKV
infection partially protected from a lethal WNV infection (Vazquez-Calvo et al., 2017). In
contrast, passive transfer of WNV-specific human plasma into Stat2 deficient mice
resulted in enhanced disease (Bardina et al., 2017). Future studies should continue to
investigate the effect of WNV pre-exposure on ZIKV disease in animal models.
The WNV-specific enhancing Abs we identified bind to the DII fusion loop (WNVE18) and the DIII lateral ridge (WNV-E24) of the E protein (Oliphant et al., 2005;
Oliphant et al., 2006), while the DENV-elicited mAb (4G2) also binds to the DII fusion
loop (Crill and Chang, 2004; Stiasny et al., 2006) (Fig. 3.1). Paul et al. identified two
human DENV-elicited mAbs that bind to the fusion loop and enhance ZIKV infection in
vitro (Paul et al., 2016). As a class, fusion loop Abs are highly cross-reactive since this
epitope is well conserved among flaviviruses (Crill and Chang, 2004; Dejnirattisai et al.,
2016). DENV-specific mAbs with different specificities have been shown to enhance
infection of DENV (Dejnirattisai et al., 2016; Halstead, 2003) although studies suggest
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that fusion loop Abs are more potent at inducing ADE than antibodies specific for other
epitopes (Dejnirattisai et al., 2016).
Several studies have demonstrated in vitro ADE of ZIKV infection of Fc receptorbearing cell lines using anti-DENV monoclonal antibodies or sera, and one study found
increased ZIKV replication in adult mice after passive transfer of human anti-DENV and
anti-WNV plasma, as described above. However, a study in which monkeys were
previously infected with DENV did not find evidence of enhanced ZIKV replication or
disease (McCracken et al., 2017), and other studies have found that DENV preexposure or DENV-specific mAbs can confer protection against ZIKV infection
(Fernandez et al., 2017; Swanstrom et al., 2016; Wen et al., 2017). Finally,
epidemiological evidence of ADE of ZIKV in humans of any age has not been presented.
Thus it remains unclear whether pre-existing immunity to DENV affects ZIKV disease.
While our study suggests that DENV-specific matAbs do not affect ZIKV infection
of infant mice, it remains unclear whether pre-existing flavivirus immunity affects ZIKV
infection and/or pathogenesis in fetuses. A pre-print study suggested that DENV-specific
matAbs may increase the incidence of ZIKV disease in fetal mice (Rathore et al., 2018),
but an epidemiological study in human infants found no association between DENVspecific matAb positivity and ZIKV infection severity, RNA load, or birth outcomes (Halai
et al., 2017), although the relationship between maternal titer and outcomes was not
investigated. The discrepant results between these two studies may be due to
differences in mouse versus human placentation or fetal development, route of antibody
transfer, viral inoculum, or insufficient power in the epidemiological study.
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Whether DENV-specific matAbs may affect disease in infants infected with ZIKV
post-natally, rather than infants born with congenital Zika syndrome, had not been
investigated previously. While our experiments suggest that DENV-specific matAbs do
not affect ZIKV disease in infants, they do not rule out such a scenario. ADE is
notoriously difficult to achieve in vivo, as it occurs within a narrow window of antibody
levels between antibody-mediated neutralization and levels too low to affect the virus
(Katzelnick et al., 2017). It is possible that we were unable to achieve sufficiently high
levels of DENV-specific matAbs in our mouse model to fall within that window. Future
studies should include experiments in large animal models such as nonhuman primates
as well as epidemiological studies in humans to establish whether previous flavivirus
exposures influence ZIKV pathogenesis. Conversely, ZIKV pre-exposure may affect
disease caused by other flaviviruses (George et al., 2017; Stettler et al., 2016; VazquezCalvo et al., 2017) and future studies should address this possibility as well. Many
vaccines and monoclonal antibody-based therapeutics for ZIKV are in development
(Diamond et al., 2018), and if ADE does indeed exacerbate disease caused by Zika
virus, the enhancing potential of these interventions must also be evaluated.
Little is known about the long-term sequelae of ZIKV infection during childhood.
A recent report found that adult mice that had survived a neonatal ZIKV infection had
impaired cognitive development and learning ability (Wu et al., 2018). A small study
found that rhesus macaques infected with ZIKV during infancy had differences in brain
structure, functional connectivity, and emotional behavior at 6-12 months post infection
(Mavigner et al., 2018). While we did not observe deleterious effects of DENV-specific
matAbs on the course of ZIKV disease over 14 days post infection, it is possible that
DENV-specific matAbs may lead to worse long-term outcomes.
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In this study, we demonstrated that maternal exposure to ZIKV via infection or
immunization with an mRNA-LNP vaccine encoding the prM and E proteins of ZIKV can
protect the offspring from ZIKV disease. Previous studies have also shown that maternal
ZIKV vaccination, either with an adenovirus-vectored vaccine or a DNA vaccine, can
provide passive protection to pups (Kim et al., 2016; Liu et al., 2018; Wang et al., 2018).
These maternal vaccination regimens required at least one booster dose. Importantly,
several studies showed that pre-pregnancy vaccination with mRNA or a live attenuated
virus reduced fetal or placental ZIKV infection (Richner et al., 2017b; Shan et al., 2017;
Xie et al., 2018). Further studies should address the use of ZIKV vaccines during
pregnancy and their use in large animal models. Ultimately, a better understanding of
how prior flavivirus exposures influence ZIKV infections will be important for
implementing new ZIKV vaccines and for understanding the unusual patterns of disease
associated with the current ZIKV outbreak.
Materials and Methods
Cells and virus
PRVABC59, a 2015 ZIKV isolate from Puerto Rico, was obtained from BEI Resources
(NR-50240). DENV-2 strain New Guinea C was obtained from BEI Resources (NR-84).
Both viruses were expanded and titrated in Vero cells (CCL-81, obtained from ATCC).
For ELISA stocks, virus was concentrated by ultracentrifugation. K562 cells, a human
erythroleukemic cell line, were a gift from J. Riley (U. Penn).
Antibodies
DENV- and WNV-elicited mAbs were obtained from BEI Resources (see Table 3.1),
except for 4G2, which was obtained either from BEI Resources, or as ascites fluid (EMD
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Millipore) and then purified over NAb Protein G Spin Column (ThermoScientific). Two
clones obtained from BEI Resources (DENV3-E11 and DENV3-E2) bound nonspecifically by ELISA or to uninfected cells and were omitted from analyses. An influenza
virus-specific mAb (170-3C12) (Yewdell et al., 1988) was also obtained from BEI
Resources. The ZIKV-elicited mAb (ZIKV-0402166) was purchased from Aalto
Bioreagents.
ELISAs
Immulon 4HBX 96-well plates (ThermoScientific) were coated overnight at 4C with
concentrated PRVABC59 or DENV-2 diluted in PBS, or PBS alone. Plates were blocked
with 3% BSA in PBS for 2h at room temperature, then washed 5x in deionized water.
mAbs or mouse sera were serially diluted in 1% BSA in PBS, added to the plates, and
incubated for 2h at room temperature. Plates were washed 5x then HRP-conjugated
anti-mouse IgG (MP Biomedicals) diluted in 1% BSA was added and incubated for 1h at
room temperature. Plates were developed with 3,3',5,5'-Tetramethylbenzidine (TMB)
SureBlue (KPL) and read with a SpectraMax 190 plate reader (Molecular Devices).
Binding curves were plotted in GraphPad Prism using one-site specific binding. mAbs
were classified as positive if binding of the mAb at a fixed concentration was >2x both
binding of the mAb to no-antigen control and binding of negative control mAb 170-3C12
to PRVABC59 in 3 independent ELISAs.
Flow cytometry binding assay
Vero cells were infected with PRVABC59 (moi 5), or left uninfected. The next day, cells
were collected and washed in 1% BSA in PBS then in PBS alone. Cells were fixed and
permeabilized with BD Perm/Fix (BD Cytofix/Cytoperm Plus Kit, BD Biosciences), then
stained with mAbs diluted to 15ug/ml in 1x Perm/Wash (BD Cytofix/Cytoperm Plus Kit,
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BD Biosciences). Cells were then stained with FITC-conjugated donkey anti-mouse IgG
(Jackson ImmunoResearch) and FITC signal evaluated by flow cytometer (LSRII, BD
Biosciences). Data were analyzed using FlowJo.
Plaque assay
Vero cells were seeded in a 6 well plate (Corning) in DMEM + 10% FBS and allowed to
grow to 90-100% confluence. Ten-fold serial dilutions of virus were made in warm
serum-free DMEM and added to cells in a volume of 100 µl. Cells were incubated with
virus at 37°C for 1 hour with rocking at 15 minute intervals and then overlaid with a 1:1
mixture of 1.4% agarose (Lonza) and 2x DMEM (Invitrogen) plaque assay media (3%
FBS, 0.07 M sodium bicarbonate, 0.017 M Hepes, L-glutamine [Corning], 0.26 µg/ml
amphotericin B [Gibco], 1x pen/strep [Corning]).
Focus reduction neutralization test (FRNT)
Vero cells were plated at 2.5 x 104 cells/well in 96 well plates (BD) the day before the
assay. mAbs and sera were serially diluted in serum-free media and mixed with a
constant amount of virus, then incubated at 37°C for 1h. Ab/virus mixtures were added
to washed cells, then incubated at 37C for 1h. Inocula were removed and cells were
washed with serum-free media, and overlaid with 1.25% Avicel RC-591 NF (FMC
BioPolymer) in plaque assay media. After incubation at 37°C for 40h, the overlay was
removed and cells were fixed with 4% paraformaldehyde (1h, 4°C) and permeabilized
with 0.5% triton-X (7 min, room temperature). Wells were blocked with 5% BSA in TBS-T
(Bio-Rad), which was used for subsequent dilutions, for 1h at room temperature. Cells
were stained with 4G2 (0.4ug/ml) for 1h at room temperature, then HRP-conjugated antimouse IgG (MP Biomedicals) diluted 1:2000 was added for 1h at room temperature.
Wells were developed with TMB TrueBlue (KPL) for 2-5h and dried overnight. Images
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were collected on an ImmunoSpot (Cellular Technology Ltd.) and foci were counted
manually.
Enhancement assay
mAbs were serially diluted in serum-free media and mixed with a constant amount of
virus, then incubated at 37°C for 1h. K562 cells were added to mAb/virus mixture to a
final moi of 0.5, then incubated for 3 days at 37°C. Cells were washed in 1% BSA in
PBS, incubated with anti-CD16/CD32 (BD Biosciences), then fixed and permeabilized
(BD Cytofix/Cytoperm Plus, BD Biosciences). Cells were stained with anti-DENV 3-E26
(NR-15527, BEI Resources) directly labeled with AF647 using Alexa Fluor 647 Protein
Labeling Kit (Molecular Probes) and data were collected by flow cytometer (LSRII, BD
Biosciences). Data were analyzed using FlowJo.
Sequence comparisons
Amino acid sequences for ZIKV PRVABC59 (KU501215.1), DENV-1 (NC_001477),
DENV-2 (NC_001474), DENV-3 (NC_001475), DENV-4 (NC_002640), and WNV
(NC_001563) E proteins were aligned using protein BLAST. Different epitopes were
highlighted on the ZIKV E protein structure (PDB ID: 5JHM) (Dai et al., 2016) using
PyMOL. For this, DIII lateral ridge residues were obtained from (Zhao et al., 2016).
Mice
All protocols were approved by the Wistar Institute’s Institutional Animal Care and Use
Committee. Adult male and female Ifnar1-/- mice were purchased from The Jackson
Laboratory and then bred in-house. Some female mice were infected with 2000 PFU
ZIKV PRVABC59 or DENV-2 intravenously via retro-orbital injection under isoflurane
anesthesia. Other female mice were immunized with 30 µg nucleoside-modified mRNA64

LNP vaccine encoding prM and E of ZIKV strain H/PF/2013 (Pardi et al., 2017). After 2
weeks, serum was collected and anti-ZIKV or DENV IgG titer was confirmed by ELISA.
Exposed or naïve female mice were mated to naïve males and delivered their pups.
Pups were weaned at 21 days old and serum was collected using 1.5 ml serum
collection tubes (Sarstedt) before infection.
Infection of infant mice
21 day old (infant) mice within each litter were distributed between ZIKV challenge and
mock groups, with male and females distributed equally. Pups were infected with 20
PFU ZIKV in 20 µl subcutaneously over the hock (ankle) (Kamala, 2007). The hock was
chosen as the injection site because footpad injection would interfere with scoring of
neurological signs. Weight and clinical signs were monitored for 14 days post infection.
Clinical signs were scored as in Table 3.2. Mice were euthanized at scores 5 and 6 and
assigned a score of 6 for subsequent days.
Quantification of viral load in tissues
Mice were infected at 21 days old and euthanized 6 days later and blood and spleen
were collected from all mice and testes collected from male mice. Blood was collected
into 1.5 ml tubes and allowed to clot at room temperature. Tubes were centrifuged at
10,000 rpm for 5 minutes at 4°C and serum was stored at -80°C until further processing.
For tissue collection, mice were perfused with sterile PBS and then organs were
collected into tubes and stored immediately on dry ice. Organs were then stored at 80°C until further processing.
RNA was extracted from sera using the QIAamp viral RNA kit (Qiagen) according to
manufacturer’s instructions. RNA was extracted from organs using the RNeasy kit
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(Qiagen) according to manufacturer’s instructions. cDNA was prepared using random
hexamer primers (Thermo Fisher Scientific), superscript III reverse transcriptase
(Invitrogen), and a constant amount of RNA. cDNA was stored at -20°C until qPCR was
performed.
qPCR was performed with primers (F 5’AGATGACTGCGTTGTGAAGC’3, R
5’GAGCAGAACGGGACTTCTTC3’), a constant amount of cDNA, and Sybr green
master mix (Applied Biosystems) on a Step One Plus machine (Applied Biosystems). Ct
values were normalized to a standard curve of known quantities of viral RNA.
Statistics
Data were graphed and analyzed using GraphPad Prism 7 (GraphPad).
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Figures and Tables
Figure 3.1

Figure 3.1. ZIKV E protein structure.
Domain 1 (DI), red; DII, yellow; DIII, blue; fusion loop, orange; and DIII lateral ridge, light
blue are highlighted on the previously published ZIKV E protein dimer structure (PDB:
5JHM) (Dai et al., 2016) using PyMOL.
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Figure 3.2

Figure 3.2. DENV- and WNV-elicited mAbs bind to ZIKV PRVABC59.
We tested a panel of mAbs for binding to ZIKV PRVABC59 (blue line) or a no-antigen
control (black line) by ELISA. Samples were run in triplicate and data are shown as
mean +/- SD. Data shown are representative of 3 independent experiments. We
included the ZIKV-0402166 mAb (ZIKV-elicited) as a positive control and 170-3C12 mAb
(influenza virus-elicited) as a negative control. Binding curves were calculated using
one-site specific binding. We tested 54 mAbs and shown are the mAbs where the ZIKV
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ELISA signal was >2x the ELISA signal of the mAb against a no-antigen control and of
the irrelevant influenza virus-specific mAb (170-3C12).
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Figure 3.3
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Figure 3.3. DENV- and WNV-elicited mAbs bind to ZIKV PRVABC59-infected cells.
We tested the mAbs identified in Figure 3.2 for binding to infected Vero cells by flow
cytometry. Vero cells were infected with ZIKV PRVABC59 at moi=5. The next day, the
cells were fixed and permeabilized and 15 µg/ml of each mAb was added, followed by
the addition of a FITC-conjugated anti-mouse IgG Ab. We included the ZIKV-0402166
mAb (ZIKV-elicited) as a positive control and 170-3C12 mAb (influenza virus-elicited) as
a negative control. Data are representative of 2 independent experiments. FI, fluorescent
intensity.
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Figure 3.4

Figure 3.4. DENV- and WNV-elicited mAbs enhance ZIKV PRVABC59 in vitro.
A, The mAbs identified in Figure 3.2 were tested for neutralization of ZIKV PRVABC59
by FRNTs in Vero cells. mAbs (initial concentration 10 ug/ml) or anti-ZIKV polyclonal
mouse sera (positive control; initial dilution 1:40) were incubated with virus at 37°C for
1h, then the inoculum was adsorbed to cells for 1h. After 40h, intracellular E protein
expression was determined using the 4G2 mAb, and the number of foci per well were
counted manually. Shown are data (mean +/- SD) compiled from 3 independent
experiments. FFU, focus forming unit. B, Next, mAbs were tested for enhancement of
ZIKV PRVABC59 infection of K562 cells. mAbs were incubated with virus at 37°C for 1h,
then added to cells. 3 days later, cells were collected and intracellular E protein
expression was determined using flow cytometry. Data (mean +/- SD) are representative
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of 3 independent experiments. C, Enhancement ability was calculated as the area under
the curve (AUC) of each mAb in B and plotted against relative binding +/- SD (as
determined by AUC; Figure 3.2).

73

Figure 3.5

Figure 3.5. Adult female Ifnar1-/- mice transfer flavivirus-specific matAbs to
offspring.
A, Adult female Ifnar1-/- mice were infected with 2000 PFU ZIKV or DENV i.v. or
vaccinated with 30 µg ZIKV prM-E mRNA-LNP vaccine i.d., or left naïve, and serum was
collected 14 days later. Serum anti-DENV (x axis) or ZIKV (y axis) antibody levels were
determined by ELISA and expressed here as O.D. at 1:200 serum dilution. B, Females
in A were mated with male Ifnar1-/- mice and allowed to have pups. 21 days after birth,
serum was collected from mothers and pups. DENV- and ZIKV-specific antibody levels
were measured by ELISA and the ratio of pup:mother sera was calculated. Each point
denotes one litter (mean of individual pup:mother ratios within that litter). Lighter colors
indicate heterologous antibody titer. Red circle, mother was infected with DENV. Blue
upright triangle, mother was infected with ZIKV. Green downwards triangle, mother was
vaccinated with ZIKV prM-E mRNA-LNP vaccine. Black diamond, naïve mother. Groups
were compared using unpaired t test. ***, p<0.001. DENV and ZIKV antigens for both
panels were normalized by mAb 4G2 staining.
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Figure 3.6
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Figure 3.6. ZIKV-specific matAbs protect infant mice from ZIKV disease.
21 day old Ifnar1-/- mice were subcutaneously infected with 20 PFU ZIKV in the absence
of flavivirus-specific matAbs (black) or in the presence of DENV-specific matAbs (red) or
ZIKV-specific matAbs from maternal infection (blue) or prM-E mRNA-LNP vaccination
(green), or mice were mock infected with PBS (gray). A, Weight was measured daily and
expressed as percentage of baseline weight. B, Percentage of baseline weight of each
mouse on day 10 post challenge. C, Correlation between percentage of baseline weight
at 10 days post infection and pre-infection ZIKV-specific serum antibody titer. Each point
represents one mouse (red circle, mother was infected with DENV; blue upright triangle,
mother was infected with ZIKV; green downward triangle, mother was vaccinated with
prM-E mRNA-LNP vaccine). R2=0.44. Dotted lines indicate 95% confidence interval. D,
Clinical scores were recorded daily for individual mice according to Table 3.2. E, Clinical
scores for each mouse on day 10 post challenge. F, Correlation between maximum
clinical score and pre-infection ZIKV-specific serum antibody titer. Each point represents
one mouse; colors and shapes as in (C). R2=0.29. Dotted lines indicate 95% confidence
interval. G, Survival was measured over 14 days post challenge. p=0.0003, log-rank test.
Mice with clinical score 5 or 6 were euthanized and assigned a score of 6 for subsequent
days. n=8-9 mice per group (no matAbs and ZIKV prM-E mRNA-LNP matAbs) or 23-28
mice per group (DENV-specific matAbs, ZIKV-specific matAbs, and uninfected). Data in
A, B, and D were compared by one-way ANOVA with Tukey’s post-test. Data in A, B, D,
E are shown as mean +/- SD. In A and D, * denotes significant difference between
uninfected mice and mice infected in the absence of matAbs (black) or in the presence
of DENV-specific matAbs (red) at each timepoint. In B and E *, p<0.05, **, p<0.01, ***,
p<0.001, ****, p<0.0001. ns, not significant.
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Figure 3.7

Figure 3.7. ZIKV-specific matAbs reduce viral load in ZIKV-infected infant mice.
21 day old Ifnar1-/- mice were subcutaneously infected with 20 PFU ZIKV in the absence
of flavivirus-specific matAbs (black diamond) or in the presence of DENV-specific
matAbs (red circle) or ZIKV-specific matAbs from maternal infection (blue upright
triangle) or prM-E mRNA-LNP vaccination (green downward triangle), or mice were
mock infected with PBS (gray square). Mice were euthanized and tissues collected 6
days post infection. ZIKV RNA was quantified in the sera (A), spleens (B), and testes
(C). n=3-16 per group for sera and spleens and 2-8 per group for testes except for the
ZIKV mRNA matAb group which had only one male mouse. Data are shown as mean +/SD. Groups were compared by one-way ANOVA with Tukey’s post-test. *, p<0.05, **,
p<0.01, ***, p<0.001, ****, p<0.0001.
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Table 3.1

Type and
clone
DENV1-E6
DENV1-E11
DENV1-E12
DENV1-E13
DENV1-E17
DENV1-E18
DENV1-E19
DENV1-E24
DENV1-E27
DENV1-E29
DENV1-E30
DENV1-E31
DENV1-E32
DENV1-E33
DENV1-E37
DENV1-E42
DENV1-E47
DENV1-E51
DENV1-E54
DENV1-E59
DENV23H5-1
DENV24G2
DENV3-E1
DENV3-E3
DENV3-E4
DENV3-E7
DENV3-E8
DENV3-E9
DENV3-E10

Crossreactivity1
DENV-2, 3

Relative
binding to
ZIKV
(AUC)

Neutralization
capacity
(FRNT50,
µg/ml)

Enhancing
ability (AUC)

Antigen
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII
whole DENV-1
and DENV-1 DIII

Isotype

Domain

Ref.

IgG1

DIII

IgG1

DIII

IgG1

DIII

IgG1

DIII

DENV-2, 3, -4
DENV-2, 3

IgG1

DI/II

ZIKV

4.29 +/0.38

IgG2a

DI/II

IgG1

DI/II

ZIKV

7.95 +/0.76

IgG1

DIII

IgG1

DIII

IgG1

DIII

IgG1

DIII

IgG1

DIII

2

IgG1

DIII

2

IgG1

DI/II

2

IgG1

DIII

IgG1

DIII

IgG1

DI/II

IgG1

DIII

2

IgG1

DIII

2

IgG2b

DIII

whole DENV-2

IgG1

DIII LR

whole DENV-2
DENV-3 E
protein and DIII
DENV-3 E
protein and DIII
DENV-3 E
protein and DIII
DENV-3 E
protein and DIII
DENV-3 E
protein and DIII
DENV-3 E
protein and DIII
DENV-3 E
protein and DIII

IgG2a

DII FL

IgG2a

DIII

8

IgG1

DI/II

8

IgG1

DI/II

8

IgG2a

DI/II

8

IgG1

DIII

8

IgG1

DI/II

8

IgG1

DI/II

8

2
2
2
2
>10

19.43

2
2

>10

5.391

2
2

DENV-3

2
2

DENV-2, 3

DENV-2, 3
DENV-2, 4, ZIKV

2

2
3.81 +/0.07

2
>10

24.56

DENV-3
panflavivirus
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2

2
3, 4
12.89 +/0.25

>10

199.7

5, 6,
7

DENV4-E71
DENV4E100
DENV4E103

DENV-3 E
protein and DIII
DENV-3 E
protein and DIII
DENV-3 E
protein and DIII
DENV-3 E
protein and DIII
DENV-3 E
protein and DIII
DENV-3 E
protein and DIII
DENV-3 E
protein and DIII
whole DENV-4
and DENV-4 DIII
whole DENV-4
and DENV-4 DIII
whole DENV-4
and DENV-4 DIII
whole DENV-4
and DENV-4 DIII
whole DENV-4
and DENV-4 DIII
whole DENV-4
and DENV-4 DIII
whole DENV-4
and DENV-4 DIII
whole DENV-4
and DENV-4 DIII
whole DENV-4
and DENV-4 DIII
whole DENV-4
and DENV-4 DIII
whole DENV-4
and DENV-4 DIII

WNV-E18

purified WNV E

IgG2a

DII FL

DENV-2,
ZIKV

WNV-E24

purified WNV E

IgG2a

DIII LR

ZIKV

WNV-E34

purified WNV E

IgG1

DIII LR

9, 10

WNV-E58

purified WNV E

IgG2a

DIII

9, 10

WNV-E101

purified WNV E

IgG2a

DI LR

9, 10

WNV-E114

purified WNV E

IgG1

DIII

WNV-E121

purified WNV E
Influenza virus
PB2

IgG2a

DI LR

DENV3-E12
DENV3-E16
DENV3-E17
DENV3-E25
DENV3-E26
DENV3-E28
DENV3-E35
DENV4-E1
DENV4-E23
DENV4-E29
DENV4-E34
DENV4-E40
DENV4-E42
DENV4-E43
DENV4-E62

170-3C12

IgG1

DI/II

8

IgG1

DI/II

DENV-1

8

IgG2a

DI/II

DENV-1

8

IgG2a

DI/II

IgG1

DI/II

IgG2b

DI/II

IgG1

DI/II

IgG2b

DIII

IgG1

DI/II

IgG1

DIII

4

IgG2a

E

4

IgG2a

DIII

4

IgG2b

E

4

IgG2b

E

4

IgG2a

E

4

IgG1

DI/II

4

IgG2c

DIII

4

IgG2c

DI/II

DENV-1, 2, ZIKV
DENV-1, 2, -4, ZIKV
DENV-1, 2
DENV-1, 2, -3
DENV-2, 3

5.02 +/0.23
4.64 +/0.20

8
>10

27.65

8

>10

35.59

8
8
4
4

11.57 +/0.58
7.18 +/0.50

4
>10

319.0

9, 10

>10

57.77

9, 10

9, 10
DENV-2

IgG2a

1.19 +/0.02

9, 10
>10

5.196

11

LR, lateral ridge. FL, fusion loop. 1As reported in references (for DENV or WNV) or as
determined in this study (for ZIKV). 2Shrestha et al., 2010, 3Henchal et al., 1982,
4
Sukupolvi-Petty et al., 2007, 5Gentry et al., 1982, 6Stiasny et al., 2006, 7Crill and Chang
2004, 8Brien et al., 2010, 9Oliphant et al., 2005, 10Oliphant et al., 2006, 11Yewdell et al.,
1988.
Table 3.1. Murine mAbs elicited by DENV and WNV used in this study.
Clone name, antigen used to elicit each hybridoma, isotype, domain specificity, crossreactivity, and reference are provided for each mAb.
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Table 3.2
Clinical score

Clinical signs

0

No clinical signs

1

Unilateral hind limb weakness and/or knuckling/toe dragging

2

Bilateral hind limb weakness or unilateral hind limb paralysis

3

Bilateral hind limb paralysis

4

Hind limb clinical signs plus weakness or paralysis, unilateral or
bilateral, in front limbs

5

Any clinical signs in limbs plus central/cranial nerve clinical signs
(e.g. circling, head tilt, eye squint)

6

Moribund

Table 3.2. Clinical scoring system for ZIKV-infected infant mice.
We assessed mice daily and assigned a score of 0-6. Mice with scores 5 or 6 were
euthanized and then assigned a score of 6 for remaining days.
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CHAPTER 4: DISCUSSION
Infants contend with a unique physiological and immunological situation. They
must transition from an environment dominated by maternal influence in utero to selfsufficiency, and are vulnerable during this transition. Many of their organ systems are not
yet in a mature, “adult” state, including the respiratory and nervous systems. The infant’s
immune system must adjust quickly to a new environment teeming with foreign
microbes, both beneficial and harmful. We need therapeutic and preventative
interventions that are tailored to infants, yet we do not know enough about the specific
adaptations of the infant immune system. In order to best protect infants, we must better
understand how the infant immune system interacts with the sheltered maternallyinfluenced environment it is leaving behind and the complex world it has entered.
The Ideal Vaccine Program
Most childhood vaccines are given during infancy with the intention to protect the
child for many years, even for a lifetime, and on the population level, this has been a
great success. However, on closer examination, there are some problems with the
current format. Only three vaccines (BCG, oral poliovirus, and hepatitis B) are given at or
near birth (Morris and Surendran, 2016; World Health Organization, 2018b), leaving a
period of months or more in which infants have not yet been vaccinated against other
agents. Furthermore, most vaccines require multiple doses to achieve full
immunogenicity, leaving yet more months in which the infants are not yet protected, and
requiring multiple visits to the clinic. One solution to these problems is maternal
vaccination, which takes advantage of the mother’s ability to transfer antibodies to her
infant. These maternal antibodies can then protect the infant until the infant’s own
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immune system can generate protective active immunity in response to exposures in the
form of infections or, preferably, vaccines. However, relying on matAbs introduces a new
set of problems: (1) matAbs can inhibit the infant’s de novo immune response and (2) in
some situations, matAbs can exacerbate disease. Therefore, we need a better strategy
for protecting infants that includes appropriate use of maternal vaccination and an
improved vaccine platform that is safe and effective in the presence of matAbs.
The mRNA-LNP vaccine offers a promising platform for infant vaccination. In
chapter two, we showed that an mRNA-LNP vaccine encoding the HA glycoprotein from
influenza virus protected infant mice from influenza infection and disease, even after
vaccination in the presence of high levels of influenza virus-specific matAbs. Importantly,
this protection required only a single, low dose (1 µg) of vaccine. In chapter three, we
found that ZIKV-specific matAbs protected infant mice from ZIKV disease. The mothers
were either infected with a low inoculum of ZIKV or vaccinated with an mRNA-LNP
vaccine encoding the prM and E proteins of ZIKV, and both exposure methods produced
high levels of ZIKV-specific matAbs in the pups. The mRNA-LNP vaccine has shown
success in large animal models and is safe and immunogenic in healthy adults (Bahl et
al., 2017; Liang et al., 2017; Lindgren et al., 2017; Lutz et al., 2017; Pardi et al., 2018a;
Pardi et al., 2017; Pardi et al., 2018c; Richner et al., 2017a). Further studies should
extend our findings here to large animal models of vaccination in the presence of
matAbs and, if those are successful, to human clinical trials, likely using an agereduction approach where the vaccine is tested in progressively younger subjects.
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Mechanism by which mRNA-LNP Vaccine Elicits Antibody Responses in the
Presence of MatAbs
It is unclear how the mRNA-LNP vaccine is able to elicit robust antibody
responses in the presence of high levels of matAbs. We showed that the PR8 HA
mRNA-LNP vaccine elicits germinal center (GC) responses at least 8 weeks post
vaccination. While the percentage of GC B cells was decreasing in mice vaccinated with
inactivated influenza virus, the percentage of GC B cells remained steady or was
increasing in mice vaccinated with the HA mRNA-LNP vaccine (Fig. 2.4), suggesting
GCs persisted longer than 8 weeks in vaccinated mice. GCs are key sites for affinity
maturation, class switching, and differentiation into memory and plasma cell subsets for
protein antigens (Mesin et al., 2016). Prolonged GC lifespans may increase all of these
important parameters. In this study we did not observe a difference in memory B cell or
plasma cell responses after mRNA-LNP vaccination in the presence and absence of
matAbs (data not shown). Future work should further evaluate memory B cell and
plasma cell pools and assess the affinity and degree of hypermutation of antibodies
elicited in these mice.
It is also unclear how the antigen reaches the lymph node. In this study we
injected the PR8 HA mRNA-LNP vaccine intramuscularly (i.m.), but we found that it can
also overcome matAb inhibition after intradermal injection (data not shown). It is possible
that parenchymal cells in the muscle or dermis take up the mRNA-LNPs after injection,
express the HA, and the antigen reaches the draining lymph node through immune
surveillance of peripheral tissues. More likely, immune cells (e.g. dendritic cells) at the
injection site may take up the mRNA-LNPs and travel to the draining lymph node, or the
mRNA-LNP particles may reach the lymph node through fluid flow. The mRNA-LNPs we
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used in this study were ~80nm, slightly smaller than those used in a study that tracked
fluorescent particles injected into the footpads of mice (Carrasco and Batista, 2007). In
that study and a similar study that used inactivated vesicular stomatitis virus (VSV) (Junt
et al., 2007), particles quickly reached the subcapsular sinus of the draining lymph node
and were taken up by subcapsular sinus macrophages (SSMs). In those studies, antigen
was handed off to B cells, which carried it to the follicle. Future studies should examine
whether SSMs take up mRNA-LNPs and if so, whether they express antigen from the
mRNA-LNPs or simply transfer it to the underlying structures. It also remains unclear
how matAbs affect these processes. A third study (Phan et al., 2007) found very similar
kinetics of lymph node entry for immune complexes (produced in vivo by injection of
protein and polyclonal antibodies) to particles. However, in our study, we observed a
delay in GC formation in mice vaccinated in the presence of matAbs (Fig. 2.4),
suggesting a delay in either antigen production, entry into the lymph node, or GC
initiation. It is possible that the amount of matAbs in our study is different than the
amount of Abs used in Phan et al., 2007, that matAbs differ in an intrinsic property such
as IgG subclass composition or glycosylation, or that infant GCs form more slowly
(Munguia-Fuentes et al., 2017). Additionally, soluble antibody may compete with B cell
receptors for antigen (Zhang et al., 2013b). As matAbs wane, more antigen becomes
available for B cell receptor interaction and the de novo antibody response can
commence.
Interestingly, we observed that the mRNA-LNP vaccine elicited GC responses in
the draining lymph node and spleen in the absence of matAb but only the draining lymph
node in the presence of matAb. Multiple studies employing varied models have reported
differences in responses in lymph nodes versus the spleen (Boyden et al., 2012; Frank
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et al., 2015; Gonzalez et al., 2010; Junt et al., 2007; Krueger et al., 1977; Lofano et al.,
2015; Yokochi et al., 1990). Many factors are likely involved, including type of antigen
(especially live versus inactivated or recombinant), dose, adjuvant, and local
inflammatory signals. There are also differences in ontogeny between secondary
lymphoid organs, leading to distinctive cell populations in the developed organ (Anjuere
et al., 1999; Ettinger et al., 1996; Moriyama et al., 2011). Interestingly, two studies found
that macrophage depletion had a large effect on the distribution of antigen or antibody.
Junt et al., 2007 found that depletion of SSMs led to the spread of live VSV from the
draining lymph node to the blood, spleen, and non-draining lymph nodes. Even more
interestingly, Gonzalez et al., 2010 found that depletion of macrophages led to increased
antibody responses to inactivated influenza virus in downstream lymph nodes and the
spleen. Although it is not known whether mRNA-LNPs interact with SSMs, matAbs may
act in a similar way to restrict antigen to the draining lymph node.
Antigen is required for positive selection of B cells in the GC to occur (Mesin et
al., 2016). Previous studies with an mRNA-LNP vaccine encoding Luciferase showed
that antigen was detectable for at least one week post vaccination, although the exact
kinetics depended on the route and dose (Pardi et al., 2018a; Pardi et al., 2015).
Persistent antigen presence greatly affects the GC, and thus antibody, response,
through several possible mechanisms, including increased availability of non-degraded
antigen and formation of immune complexes (Cirelli and Crotty, 2017). A recent study
demonstrated that delivering antigen in exponentially increasing doses over two weeks
resulted in a higher serum antibody response than delivering the same total amount of
antigen as a bolus (Tam et al., 2016). This study used a protein antigen with an adjuvant
and required up to 14 injections, which is not practical in the clinic. In contrast, mRNA85

LNP vaccination provides extended antigen availability and requires only one injection.
In ongoing studies, we are mechanistically addressing whether prolonged antigen
expression is required for the efficacy of the HA mRNA-LNP vaccine in the presence of
matAbs by taking advantage of a system termed “small molecule assisted shutoff” or
SMASh (Chung et al., 2015; Fay et al., 2018). This system employs a SMASh tag,
consisting of a self-excising degron under the control of a commercially available small
molecule protease inhibitor. Importantly, under steady state conditions, the target protein
is in its native, untagged form. Administration of the small molecule inhibitor at different
times post-vaccination will allow control over the length of time that antigen is expressed
from the mRNA.
Recruitment of naïve antigen-specific B cells throughout the lifespan of GCs may
be important for the breadth of the antibody response (Schwickert et al., 2009; Tas et al.,
2016; Turner et al., 2017), a highly desirable characteristic for a vaccine, especially one
intended to protect against a rapidly changing antigen such as influenza virus HA
(Baumgarth, 2013). A recent study (Turner et al., 2017) showed that naïve B cells did
not efficiently enter the GC, but B cells pre-loaded with antigen could join GC reactions.
It is possible that matAb-antigen immune complexes may facilitate the entry of B cells
into GCs, thus expanding the pool of responding B cells.
Adjuvants can have significant effects on the formation and longevity of GCs
through antigen deposition and/or modulating innate immune signals. Interestingly, the
results of the study described above (Tam et al., 2016), that demonstrated improved GC
responses after an extended delivery schedule versus the same amount of antigen
delivered in a bolus, relied on the adjuvant monophosphoryl lipid A, as protein alone was
not as immunogenic even when delivered on the same extended schedule. Although
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depots can supply antigen over time (Cyster, 2010), protein antigens in alum
nevertheless lead to relatively short-lived GCs that end several weeks after vaccination
(Kasturi et al., 2011; Mesin et al., 2016). Germinal centers peak in the draining lymph
node around 28 days after intranasal influenza virus infection in mice and are detectable
for 140 days (Rothaeusler and Baumgarth, 2010), while the maximum GC response we
observed after inactivated virus vaccination occurred around 14 days and by 56 days
post vaccination the response had fallen by approximately half (Fig. 2.4). Longer GC
persistence after infection than inactivated virus vaccination may be due to a
combination of antigen expansion and innate immune signaling during infections. The
LNP itself in the mRNA-LNP vaccine appears to have adjuvant activity, as mRNA-LNPs
encoding the irrelevant protein Luciferase were able to greatly boost antibody responses
to recombinant PR8 HA protein in naïve adult mice (Pardi et al., 2018a). Future studies
should investigate the adjuvant potential of LNPs, including through concurrent
administration of inactivated virus and LNPs to infant mice in the presence of matAbs.
In summary, the mRNA-LNP vaccine expresses antigen for an extended period
of time, and the antigen likely reaches the draining lymph node via fluid flow or after
uptake by immune cells at the site of injection. It is also unknown which cell type(s) take
up the LNPs although preliminary immunofluorescence data (not shown) suggest it is not
myocytes. MatAbs may affect the kinetics and location of GC responses by governing
the access of antigen to secondary lymphoid organs. As matAbs wane, it is possible that
antigen continues to be expressed and/or held by follicular dendritic cells and drives GC
persistence, producing the observed long-lasting antibody responses.
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Alternative Approaches to Overcoming MatAb Inhibition
While the mRNA-LNP vaccine offers a promising option for effective vaccination
of infants in the presence of matAbs, other approaches may also succeed. We can
extend the lessons learned in this and previous studies to assemble a set of
characteristics for such an approach.
(1) The vaccine should be given as early as possible, when matAb levels are
high. One current approach to vaccinating infants in the presence of matAbs is
avoidance: wait to vaccinate until matAbs have waned to a non-interfering level. This is
most clearly implemented in measles vaccination programs, in which children are not
vaccinated until 9-12 months of age due to matAb inhibition of vaccine responses
(Edwards, 2015). However, as discussed above, this approach leaves a window of
vulnerability in which matAbs are too low to provide protection but the child has not yet
generated their own active immunity. Theoretically, one could personalize vaccination
schedules according to individuals’ matAb waning kinetics to shorten this window.
However, this is not feasible on a population level due to the time and financial costs of
multiple clinic visits, blood collections, and serological assays, and so a vaccine given
early when matAb levels are high is required. We have tested the mRNA-LNP vaccine in
21-day-old infant mice. Further studies should test this vaccine in neonatal mice to
ascertain whether it works well in this age group.
(2) The vaccine should be effective after a single dose. Because it is not feasible
to time a child’s vaccination schedule to his or her individual matAb waning kinetics and
due to some vaccines’ low immunogenicity, many childhood vaccines require multiple
doses. While this is an adequate workaround for now, it would be better to use a single
dose before matAbs wane. We showed that the mRNA-LNP vaccine elicited robust and
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protective Ab responses after a single dose in the presence of matAbs. Single doses of
a DNA vaccine encoding a herpes simplex virus protein in mice (Manickan et al., 1997)
and virally vectored vaccines in chickens (Bublot et al., 2007; Kilany et al., 2015; SarfatiMizrahi et al., 2010) showed some promise in the presence of matAbs although these
studies did not achieve complete protection from challenge.
As described above, extended antigen availability improves GC responses and
may be a key mechanism by which vaccines can overcome matAb inhibition. In order to
combine single-dose administration with extended antigen availability, the vaccine must
either express antigen over an extended time period or provide a depot. The mRNA-LNP
vaccine provides antigen over an extended period of time, in contrast to bolus delivery
systems such as a single injection of inactivated virus.
(3) The vaccine should be safe. While currently used vaccines have undergone
clinical trials to demonstrate safety and efficacy, any new vaccines will need to undergo
thorough evaluation. Because mRNA-LNP vaccines are non-replicating and nonintegrating, they are likely to be quite safe. Indeed, their safety profile has been
satisfactory in adult clinical trials (Bahl et al., 2017; Kranz et al., 2016; Kubler et al.,
2015; Rittig et al., 2011, 2016; Sebastian et al., 2011; Weide et al., 2008; Weide et al.,
2009) but must still be evaluated in children and infants.
(4) The vaccine should contain a realistic amount of antigen. MatAbs inhibit de
novo antibody responses in a dose-dependent manner, and so one possible approach to
overcoming matAb inhibition would be to overwhelm the antibody:antigen ratio with
excess antigen (Bailey et al., 1998; Burtonboy et al., 1991; Coyne, 2000; Elazab et al.,
2010; Hsieh et al., 2010). While this may be feasible for some antigens, there is a limit to
how much antigen can be included in a vaccine, especially for pathogens with multiple
strains or serotypes such as influenza virus or pneumococcus. Furthermore, a high-dose
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measles vaccine developed in an attempt to overcome matAb inhibition resulted in
increased mortality in girls (Garenne et al., 1991). Replication-competent live vaccines
expand to high antigen loads in vivo in a naïve individual, but are likely neutralized by
matAbs. Nucleic acid vaccines that enable expression of antigen in vivo may be a
method of injecting low amounts of material but providing high amounts of antigen to the
immune system.
(5) The vaccine may require an adjuvant. As discussed above, adjuvants can
have marked effects on GC responses. Furthermore, neonatal immunity is biased
toward a Th2 response (Faucette et al., 2015; Forsthuber et al., 1996; Palmeira et al.,
2012; Ridge et al., 1996). To be effective in infants, vaccine platforms may require
adjuvants specifically tailored to this age group. A recent study (Vono et al., 2018)
showed that several novel adjuvants were able to elicit T follicular helper (Tfh) cells but
only two C-type lectin agonists induced GCs after a single dose in neonatal mice.
Previous work has shown that the mRNA-LNP vaccine induces strong Tfh responses in
adult mice and nonhuman primates, possibly due to adjuvanticity of the LNP (Pardi et
al., 2018a). In chapter two, we showed that the mRNA-LNP vaccine induces GC
responses after a single dose. Further studies should assess the adjuvant potential of
LNPs in infants.
Although we have focused on the mRNA-LNP vaccine here, other vaccine
platforms may also solve the problem of eliciting protective immune responses in the
presence of matAbs. DNA vaccines and virally-vectored vaccines, similarly to mRNAbased vaccines, do not include antigen itself in the vaccine and thus may avoid matAb
binding. They may also have other immunostimulatory qualities, such as CpG motifs,
that could provide an adjuvant effect (Bot and Bona, 2002). One study in neonatal mice
demonstrated that a naked DNA vaccine encoding the herpes simplex virus gB could
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elicit immune responses in the presence of matAbs, although mice were not fully
protected from challenge (Manickan et al., 1997). However, other DNA vaccines have
been less successful (Bot and Bona, 2002; Chen et al., 2007; Monteil et al., 1997;
Pertmer et al., 2000; Radu et al., 2001; Siegrist et al., 1998; Weeratna et al., 2001). DNA
vaccines have been licensed for veterinary applications but vaccines using this platform
have lacked sufficient immunogenicity in humans (Porter and Raviprakash, 2017). Virally
vectored vaccines have received considerable attention for application in the poultry
industry. Multiple different vectors (turkey herpesvirus, Newcastle disease virus, or
Marek’s disease virus) appear promising in overcoming matAb inhibition in birds (Bertran
et al., 2018; Bublot et al., 2007; Lardinois et al., 2016; Sakaguchi et al., 1998; SarfatiMizrahi et al., 2010; Yu et al., 2017b; Zhou et al., 2010). However, virally vectored
vaccines in young mammals have met with limited success (Capozzo et al., 2004;
Ramirez et al., 2010; Welter et al., 2000).
Sequential Use of mRNA Vaccines
In these studies, we applied the mRNA-LNP vaccine only once in each
experiment, to either the mother or the infant. However, in a comprehensive vaccination
program, it is likely that this vaccine might be used sequentially, either in a single
individual over time or in mother/infant pairs. This is especially important in the case of
influenza virus due to antigenic drift. The HA genes of circulating influenza viruses
accumulate mutations over time due to immune pressure, necessitating updated vaccine
strain selections and yearly influenza vaccination (Gerdil, 2003). In most cases, the
strains a woman has been exposed to through infection or vaccination will be different
from the strains from which her infant must be protected. Importantly, an H1 mRNA-LNP
vaccine protected mice from a distantly related H1 challenge after one dose, and from
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an H5 challenge after two doses (Pardi et al., 2018c). Future studies should examine
how HA mRNA-LNP vaccination of infants performs in the presence of unmatched
matAbs or a drifted challenge virus. It is also unknown whether matAbs generated after
mRNA-LNP vaccination of mothers would inhibit vaccination of infants in the same way
as matAbs elicited by infection or conventional vaccines.
Priming of a Humoral Response in the Presence of MatAbs
While matAbs consistently inhibit serum antibody responses after the primary
dose of a vaccine, there is some evidence that the memory B cell response may be
primed during this first antigen exposure. A study found that mice immunized with
measles virus at 3 weeks of age in the presence of matAbs generated a serum antibody
response only if they had been primed at 1 week of age (Siegrist et al., 1998). Another
study in foals found a similar result using a canarypox-vectored recombinant influenza
vaccine (Minke et al., 2007). Two studies of hepatitis A vaccination in infants found
evidence of anamnestic responses after a booster dose, suggesting priming during the
initial dose in the presence of matAbs (Dagan et al., 2000; Fiore et al., 2003).
Such priming of memory responses and concurrent suppression of plasma cell
responses has interesting implications for the mechanism of matAb inhibition. First, it
suggests that there is sufficient antigen for B cell priming and matAb-mediated direct
neutralization plays less of a role. This is especially interesting because one of the
studies described above used live measles virus vaccine (Siegrist et al., 1998). Second,
this priming suggests that either naïve B cells preferentially differentiate into memory B
cells or that plasma cells more readily undergo apoptosis. The differentiation of activated
B cells into memory B or plasma cells depends on B cell receptor affinity, with higher
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affinity B cells preferentially becoming plasma cells (Paus et al., 2006; Phan et al., 2006;
Smith et al., 1997). The memory B versus plasma cell fate decision may also depend on
time post exposure, although since affinity increases as the GC reaction progresses
these two factors may be interdependent (Mesin et al., 2016). MatAbs could dampen the
affinity of antigen-specific B cells through limiting the GC reaction or antigen availability.
Alternatively, matAbs may redirect B cells to enter the memory path regardless of BCR
affinity. Immune complex-induced apoptosis of plasma cells has been suggested as a
mechanism for making space in the bone marrow niche for new plasma cells during
secondary immune responses (Nimmerjahn and Ravetch, 2008), but could explain here
how matAbs limit the plasma cell pool. Finally, limited or delayed GC responses in
infants lead to reduced affinity maturation and delayed class switching and may
predispose infant B cells to memory rather than plasma cell fate (Siegrist and Aspinall,
2009).
T Cell Responses in the Presence of MatAbs
The evidence for matAb inhibition of antibody responses is clear and consistent
(Hodgins and Shewen, 2012; Siegrist, 2003). However, whether T cell responses are
affected by matAbs is controversial. Some reports have suggested that matAbs inhibit
the neonatal T cell response in monkeys (Premenko-Lanier et al., 2006), mice (Xiang
and Ertl, 1992), or pigs (van Rooij et al., 2006). Others suggest that the primary T cell
response after measles vaccination in human infants is functional (Gans et al., 1999)
and that vaccination in the presence of matAbs can elicit T cell responses in animal
models (Bandrick et al., 2014; Capozzo et al., 2004; Hassett et al., 1997; Pomorska-Mol
et al., 2010; Rigato et al., 2012; Sandbulte et al., 2014; Sedegah et al., 2003; Van Loock
et al., 2004; Weeratna et al., 2001). One study showed that neonatal mice with and
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without matAbs generated similar profiles of IFNγ and IL-5 production after immunization
with measles vaccine (Siegrist et al., 1998). Several reports have demonstrated that
vaccination in the presence of matAbs can protect from subsequent challenge even after
inhibition of a de novo antibody response, suggesting T cell-mediated protection
(Endsley et al., 2003; Lawhorn et al., 1994; Morgan et al., 1993). In this study, we did not
investigate whether the mRNA-LNP vaccine elicited T cell responses. We showed,
however, that passively transferred sera from mice vaccinated with PR8 HA mRNA-LNP
in the presence of matAbs could protect recipient mice from influenza (Fig. 2.3d),
suggesting that cytotoxic T cell responses are not required for protection afforded by this
vaccine.
Immune complexes (ICs) can affect T cell responses in a variety of ways (Brady,
2005). ICs are taken up more efficiently by antigen presenting cells than antigen alone,
which may be an Fc-mediated process (Manca et al., 1991; Regnault et al., 1999).
Antigens may be processed differently when bound by antibody, as suggested by altered
in vitro proteolysis and simultaneous enhanced and suppressed presentation of different
peptide epitopes with a monoclonal antibody (Simitsek et al., 1995). They may be more
likely to enter the cross-presentation pathway (Gil-Torregrosa et al., 2004; Regnault et
al., 1999; Villinger et al., 2003) which enhances cytotoxic T cell responses to pathogens
which do not normally infect antigen presenting cells (APCs). APCs that have taken up
ICs rather than antigen alone, or the T cells they interact with, may generate a different
cytokine profile (Anderson and Mosser, 2002; Janczy et al., 2014). Interestingly, one
study (Zheng et al., 2007) found that immune complexes consisting of inactivated
influenza virus and anti-nucleoprotein (anti-NP) monoclonal antibody produced more
robust cytotoxic T cell responses in aged mice than immunization with inactivated virus
alone. The studies described above were all performed in adult animals and many with
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monoclonal antibodies. It remains unclear whether these effects also play a role in how
polyclonal maternally transferred antibodies influence infant T cell responses.
Th1/Th2 Bias After Infant Vaccination
As described above, infants are predisposed to Th2 immune responses.
However, ideally, a vaccine would elicit a balanced or Th1-polarized immune response
to protect from future viral challenges. In chapter two, we showed that the PR8 HA
mRNA-LNP vaccine elicits a balanced Th1/Th2 response in naïve infant mice as
measured by IgG2a and IgG1 antibody responses (Fig. 2.3E). However, vaccination in
the presence of matAbs resulted in a Th2-skewed response. Ongoing experiments are
assessing whether the Th2 bias we observed after mRNA-LNP vaccination in the
presence of matAbs can be recapitulated using passively transferred monoclonal
antibody in adult mice (E. Goodwin). There is some evidence that incubation of antigen
presenting cells with immune complexes can lead to production of type 2 cytokines
(Anderson et al., 2002; Anderson and Mosser, 2002). Additionally, an inactivated split
influenza vaccine preparation used in the 2000-2001 season in Canada was associated
with type 2-like adverse events in human vaccine recipients and type 2 cytokine
production in mice (Babiuk et al., 2004). Interestingly, the adverse event-associated
vaccine preparation contained a high percentage of aggregated virions. It is unclear
whether aggregated virions would lead to Th2 responses through the same mechanism
as antibody-antigen complexes.
Another potential explanation for the Th2 skewing of antibody responses elicited
by the mRNA-LNP vaccine in the presence of matAbs could be due to the amount of
antigen, as matAbs may decrease the amount of effective antigen available to prime T
cells after vaccination. Antigen dose affects the differentiation of CD4+ T cells through
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qualitative differences in T cell receptor signaling with higher doses of antigen or higher
affinity peptide generally leading to Th1 responses and lower antigen dose or affinity to
Th2 responses (Tubo and Jenkins, 2014; van Panhuys, 2016). It is also possible that the
LNP formulation influences the polarization we observed, although this hypothesis is
less likely because the Th1/Th2 response was balanced in the absence of matAbs.
Antigen load likely interacts with the cytokine milieu and other innate signals in a
complex way to determine Th1 versus Th2 differentiation after vaccination. Finally, it is
possible that the location of T cell priming and differentiation, i.e. in the spleen versus
draining lymph node, affects the Th1/Th2 balance after mRNA-LNP vaccination in the
presence of matAbs.
Enhanced Disease
We have focused thus far on the use of vaccination strategies to overcome
matAb inhibition of de novo immune responses. In some contexts, matAbs present a
further problem in that they can exacerbate disease rather than protecting the infant.
This phenomenon has been most well studied for DENV, in which matAbs have been
epidemiologically linked to severe disease manifestations in children under 1 year of age
(Chau et al., 2008; Halstead, 1970; Halstead et al., 2002; Halstead et al., 1970; Kliks et
al., 1988). In chapter three, we found that DENV- and WNV-specific monoclonal
antibodies can enhance ZIKV infection in vitro but that DENV-specific matAbs do not
affect ZIKV disease in infant mice. It is possible that we did not achieve sufficient levels
of DENV-specific matAbs to demonstrate ADE, although the DENV-specific titers in
DENV-infected mothers were similar to the ZIKV-specific titers in ZIKV-infected mothers.
Other studies have investigated whether DENV-specific matAbs affect ZIKV infection of
fetuses, but the findings are mixed (Halai et al., 2017; Rathore et al., 2018), and so the
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question of whether DENV-specific matAbs enhance ZIKV disease remains
unanswered.
Although disease enhancement from prior immunity is most well studied for
flaviviruses, this phenomenon does occur in other systems. An investigational formalininactivated alum-adjuvated respiratory syncytial virus (RSV) vaccine caused enhanced
disease in vaccine recipients, characterized by increased lung inflammation (Openshaw
et al., 2017). Disease enhancement in these children is attributed in part to a Th2polarized response, non-neutralizing antibodies, and deposition of immune complexes.
Feline infectious peritonitis (FIP) is a fatal disease of domestic and wild cats
characterized by vascular damage, similar to severe forms of dengue. FIP virus (FIPV),
which infects macrophages, is thought to arise from feline enteric coronavirus (FECV),
which infects enterocytes, by mutation in individual cats, but this process remains
unclear (Poland et al., 1996). The course of FIP is accelerated in seropositive cats
(Weiss and Scott, 1981b, c) and this result can be reproduced by administration of
immune serum or anti-FIPV IgG (Petersen and Boyle, 1980; Weiss and Scott, 1981a). In
vitro, FIPV infection of feline macrophages was enhanced by FIPV-specific feline
immune serum and monoclonal antibodies specific to the FIPV spike protein (Olsen et
al., 1992). This antibody-dependent enhancement was shown to be dependent on the Fc
receptor (Olsen et al., 1992). In contrast to DENV, ADE of FIP appears to occur upon
infection with the same viral serotype rather than a heterologous virus (Takano et al.,
2008).
Exacerbated disease can occur after influenza vaccination in swine, a process
termed vaccine-associated enhanced respiratory disease or VAERD (Rajao et al., 2014).
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VAERD typically occurs during challenge with an antigenically distinct virus after
vaccination with whole inactivated virus vaccine, but can occur during infection in the
presence of matAbs (Kitikoon et al., 2006; Pyo et al., 2015; Rajao et al., 2014; Vincent et
al., 2012). Interestingly, one study found an association between VAERD severity and
cross-reactive antibodies that bind near the fusion peptide in the stalk domain of HA and
enhance fusion activity (Khurana et al., 2013). This finding has implications for the
development of universal stalk-targeting influenza vaccines. However, it remains unclear
whether VAERD is limited to pigs or occurs in other species, including humans.
Concluding Remarks
The transition from the protected intrauterine environment to a world teeming
with microbes must be managed carefully. The mother can continue to exert influence
over the infant’s development through maternally derived factors that on the whole
benefit the infant but can in some contexts be harmful. Many maternally derived
immune-related factors such as cytokines or complement components affect the infant,
but the most prominent is maternal antibodies. We have shown that matAbs protect
infant mice from influenza and Zika virus infections, but inhibit de novo antibody
responses. An mRNA-LNP vaccine overcomes matAb inhibition through persistent
germinal center formation. Many questions remain unanswered, including the precise
mechanism by which the mRNA-LNP vaccine elicits antibody responses in the presence
of matAbs. Future studies should continue to investigate the use of novel vaccine
platforms so as to formulate appropriate vaccination strategies to protect infants.
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